{"gene":"CAMP","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1995,"finding":"The human CAMP gene (then called FALL39) encodes a cathelin-type precursor protein of 170 amino acids; the mature antibacterial peptide LL-37 is derived from the C-terminal domain (exon 4) after processing, and synthetic FALL-39/LL-37 has potent antibacterial activity against Gram-negative and Gram-positive bacteria. The gene is expressed in bone marrow and testis.","method":"cDNA cloning from bone marrow library, PCR, RNA blot, chemical synthesis and antimicrobial assay, CD spectroscopy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original gene characterization with multiple orthogonal methods; replicated by multiple labs","pmids":["7529412"],"is_preprint":false},{"year":1995,"finding":"Human CAP18 (CAMP gene product) is expressed specifically in granulocytes; its C-terminal 37-amino-acid domain (CAP18(104-140), equivalent to LL-37) binds LPS, inhibits LPS-induced nitric oxide release from macrophages, inhibits LPS-induced tissue factor generation, and protects mice from LPS lethality.","method":"cDNA cloning from bone marrow library, Western blot with specific antiserum, synthetic peptide antimicrobial and LPS-binding assays, in vivo mouse endotoxemia model","journal":"Infection and immunity","confidence":"High","confidence_rationale":"Tier 1–2 — multiple in vitro and in vivo assays; replicated across labs","pmids":["7890387"],"is_preprint":false},{"year":1996,"finding":"The FALL39/CAMP gene has four exons spanning ~1963 bp; exons 1–3 encode the signal sequence and cathelin region, while exon 4 encodes the mature LL-37 peptide. The gene is the only cathelicidin family member in the human genome. Dipeptidyl-peptidase I processing of synthetic FA-LL-37 yields mature LL-37, which is isolated from degranulating granulocytes.","method":"Genomic sequencing, exon mapping, anti-LL37 IgG immunolocalization in granulocytes, dipeptidyl-peptidase I processing, antibacterial assay","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — complete gene structure determined with functional validation; foundational paper","pmids":["8681941"],"is_preprint":false},{"year":1996,"finding":"The human CAP18 (HCAP18) gene maps to chromosome band 3p21.3, contains 4 exons spanning ~3 kb with ~700 bp upstream sequence, lacks typical TATA or CCAAT boxes, and is expressed specifically in granulocytes as shown by Western, Northern blot and RT-PCR.","method":"Genomic phage library cloning, somatic cell hybrid panel PCR mapping, fluorescence in situ hybridization (FISH), Northern blot, RT-PCR, Western blot, promoter mapping in COS7 cells","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1–2 — chromosomal mapping and expression characterization with multiple methods","pmids":["8946956"],"is_preprint":false},{"year":1995,"finding":"The solution structure of the active C-terminal domain of rabbit CAP18 (CAP18(106-137)) in 30% TFE determined by NMR is a complete, rigid amphipathic alpha-helix. In the presence of lipid A, CAP18(106-137) adopts at least three lipid A concentration-dependent helical conformations, and the cationic and hydrophobic groups segregate to interact with lipid A via coulombic and hydrophobic interactions.","method":"Circular dichroism (CD) spectroscopy, NMR spectroscopy in TFE, interaction studies with lipid A","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — NMR structure determination with functional (lipid binding) validation","pmids":["7649303"],"is_preprint":false},{"year":1997,"finding":"The CAMP gene encoding LL-37 is not expressed in normal human skin keratinocytes but is strongly induced in keratinocytes during inflammatory skin disorders (psoriasis, atopic dermatitis, wound healing). In situ hybridization and immunohistochemistry localized the transcript and peptide to keratinocytes throughout inflamed epidermis, and fractions from psoriatic scales exhibited antibacterial activity.","method":"In situ hybridization, immunohistochemistry, Northern blot, antibacterial assay of psoriatic scale fractions","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple methods, widely replicated; foundational expression/function paper","pmids":["9182550"],"is_preprint":false},{"year":1998,"finding":"The conformation-dependent antibacterial activity of LL-37 was established: LL-37 is disordered in water at low concentration but adopts a cooperative alpha-helical oligomeric structure induced by anions (HCO3−, SO4 2−, CF3CO2−) or increasing peptide concentration. The degree of alpha-helicity directly correlates with antibacterial activity against both Gram-positive and Gram-negative bacteria. Serum inhibits both antibacterial and cytotoxic activities.","method":"Circular dichroism (CD) spectroscopy, minimum inhibitory concentration (MIC) assay, cytotoxicity assay, serum inhibition experiment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — structure-function relationship established by CD and activity assays with multiple peptide variants","pmids":["9452503"],"is_preprint":false},{"year":1998,"finding":"Apolipoprotein A-I (apoA-I) is the principal LL-37 binding protein in human plasma. ApoA-I was isolated by LL-37 affinity chromatography and binds LL-37 with an apparent Kd in the low micromolar range (surface plasmon resonance). ApoA-I at 50 µM inhibits ~50% of LL-37 antibacterial activity, and anti-apoA-I IgG blocks plasma inhibition of LL-37, indicating apoA-I acts as a scavenger of LL-37 in plasma.","method":"Affinity chromatography, SDS-PAGE, amino acid sequence analysis, surface plasmon resonance (Biacore), antimicrobial assay, blocking with anti-apoA-I antibody","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — binding partner identified by affinity chromatography plus kinetics by SPR, functional inhibition confirmed","pmids":["9837875"],"is_preprint":false},{"year":1998,"finding":"CAP18/LL-37 is expressed in developing neutrophils in human bone marrow in a lineage- and stage-specific manner: CAMP mRNA is transcribed predominantly at the myelocyte stage, while CAP18 protein accumulates and persists through metamyelocytes, band cells, and segmented neutrophils, indicating post-transcriptional regulation and cytoplasmic storage.","method":"Northern blot, Western blot, in situ hybridization, immunohistochemistry of bone marrow cells and mature neutrophils","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods defining spatial and temporal gene expression during differentiation","pmids":["9850169"],"is_preprint":false},{"year":2000,"finding":"LL-37 is chemotactic for human peripheral blood monocytes, neutrophils, and T lymphocytes via formyl peptide receptor-like 1 (FPRL1). LL-37 induces Ca2+ mobilization in monocytes and FPRL1-transfected HEK293 cells, and this mobilization is cross-desensitized by an FPRL1-specific agonist, establishing FPRL1 as a functional receptor for LL-37-mediated leukocyte chemotaxis.","method":"Chemotaxis assay, Ca2+ mobilization assay in monocytes and FPRL1-transfected HEK293 cells, cross-desensitization experiment","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — receptor identified by transfection and cross-desensitization; replicated across multiple cell types","pmids":["11015447"],"is_preprint":false},{"year":2000,"finding":"LL-37 is expressed by specific lymphocyte and monocyte populations including NK cells, γδ T cells, B cells, and monocytes/macrophages but not αβ T cells. Primary lymphocyte cultures transcribe and secrete LL-37, and this is modulated by IL-6 and IFN-γ. LL-37 has chemotactic activity for PMNs and CD4+ T lymphocytes.","method":"RT-PCR of cell lines, double-staining immunohistochemistry, primary lymphocyte culture, chemotaxis assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple cell types characterized with RT-PCR and immunohistochemistry; replicated","pmids":["11049988"],"is_preprint":false},{"year":2001,"finding":"The human cathelicidin hCAP-18 is cleaved extracellularly by proteinase 3 (from azurophil granules) to generate the active antimicrobial peptide LL-37. Cleavage occurs after exocytosis, not during phagocytosis. Of the three serine proteases from azurophil granules (elastase, cathepsin G, proteinase 3), only proteinase 3 was responsible for this processing.","method":"Immunoelectron microscopy, immunoblotting of exocytosed material, selective protease inhibitors, identification of cleaving protease among the three azurophil serine proteases","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — processing enzyme definitively identified with multiple proteases tested; widely cited foundational paper","pmids":["11389039"],"is_preprint":false},{"year":2001,"finding":"CAP18 (hCAP18/LL-37) and guinea pig CAP11 inhibit LPS-induced TNF-α expression in macrophages by blocking LPS binding to CD14+ cells. Mechanistically, CAP18 binds LPS with high affinity, competes with LPS-binding protein (LBP) for LPS transport to CD14, and also binds directly to cell surface CD14, thereby blocking LPS-CD14 interaction.","method":"Flow cytometry (FITC-LPS binding), Northern blot, Western blot for TNF-α, LPS-binding activity assay, LBP competition assay, in vivo mouse endotoxin shock model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway (LPS→LBP→CD14) dissected with multiple methods in vitro and in vivo","pmids":["11544322"],"is_preprint":false},{"year":2002,"finding":"LL-37 is a multifunctional immunomodulator: at physiological concentrations it inhibits LPS, lipoteichoic acid, and noncapped lipoarabinomannan stimulation of macrophages; protects mice from lethal endotoxemia; directly up-regulates 29 macrophage genes including chemokines (MCP-1, IL-8) and chemokine receptors (CXCR-4, CCR2, IL-8RB) without inducing TNF-α; and reduces NF-κB nuclear translocation (p50 and p65 reduced >50%) in LPS-treated cells.","method":"Gene expression microarray, RT-PCR, ELISA, NF-κB nuclear translocation assay, in vivo mouse endotoxemia survival assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — comprehensive transcriptional profiling plus mechanistic NF-κB pathway validation in vitro and in vivo","pmids":["12244186"],"is_preprint":false},{"year":2003,"finding":"LL-37/hCAP-18 induces angiogenesis via formyl peptide receptor-like 1 (FPRL1) expressed on endothelial cells. LL-37 directly activates endothelial cell proliferation and tube formation in vitro, promotes neovascularization in the chorioallantoic membrane assay and a rabbit hind-limb ischemia model, and mice deficient for CRAMP (the murine ortholog) show decreased vascularization during wound repair in vivo.","method":"In vitro endothelial cell proliferation and tube formation assay, chorioallantoic membrane (CAM) angiogenesis assay, rabbit hind-limb ischemia model, CRAMP-knockout mouse wound healing model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — receptor identified, in vitro mechanism validated, confirmed in vivo with genetic knockout","pmids":["12782669"],"is_preprint":false},{"year":2003,"finding":"LL-37 is expressed in healing skin epithelium and is required for re-epithelialization. hCAP18 levels peak at 48 h post-wounding then decline; it is detected in inflammatory infiltrate and migrating epithelium. In an ex vivo organ culture wound model, anti-LL-37 antibodies inhibit re-epithelialization in a concentration-dependent manner and abolish Ki67 (proliferation marker) staining in wound-edge epithelium. LL-37 is markedly reduced in chronic non-healing ulcers.","method":"Immunohistochemistry, in situ hybridization, ex vivo wound healing organ culture model with blocking antibody, Ki67 proliferation assay","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 — functional blocking antibody experiment in ex vivo model with proliferation readout","pmids":["12603850"],"is_preprint":false},{"year":2003,"finding":"LL-37 disrupts lipid bilayers via a toroidal pore mechanism. Solid-state 15N NMR of site-specifically labeled LL-37 in oriented lipid bilayers shows the amphipathic helix lies parallel to the bilayer surface (ruling out barrel-stave mechanism). 31P NMR shows no micelle/small fragment formation (ruling out detergent-like mechanism), and LL-37 increases the lamellar-to-inverted hexagonal phase transition temperature of PE and E. coli lipids, indicating positive curvature strain consistent with toroidal pore formation.","method":"Solid-state 15N NMR (chemical shift and dipolar-shift spectroscopy of isotopically labeled peptide in oriented bilayers), 31P NMR, model membrane lipid phase transition analysis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct structural NMR evidence with multiple membrane systems eliminating alternative mechanisms","pmids":["12767238"],"is_preprint":false},{"year":2004,"finding":"LL-37 activates the P2X7 receptor to induce caspase-1 activation, IL-1β processing and release from LPS-primed monocytes. LL-37 induces transient ATP release, membrane permeability changes, and IL-1β secretion without cytotoxicity. Pretreatment with P2X7 inhibitors (oxidized ATP, KN04, KN62) suppresses IL-1β release. Apyrase (which hydrolyzes ATP) does not block LL-37's effect, indicating LL-37 directly activates P2X7 rather than acting via autocrine ATP.","method":"IL-1β ELISA, caspase-1 activity assay, membrane permeability assay, pharmacological P2X7 inhibitors, apyrase treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — P2X7 as direct receptor established using multiple inhibitors and apyrase control","pmids":["15067080"],"is_preprint":false},{"year":2004,"finding":"The C-terminal domain of hCAP18 (hCAP18(109-135)) induces caspase-independent apoptosis selectively in oral squamous cell carcinoma (SAS-H1) cells but not in normal human gingival fibroblasts or HaCaT keratinocytes. The mechanism involves mitochondrial membrane depolarization without caspase activation.","method":"Cell viability assay, mitochondrial depolarization assay (JC-1), caspase activation assay, specificity comparison between cancer and normal cells","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway (mitochondrial depolarization, caspase-independent) identified in single study","pmids":["15279899"],"is_preprint":false},{"year":2006,"finding":"TLR2/1 activation of human macrophages upregulates expression of vitamin D receptor and vitamin D-1-hydroxylase, leading to induction of cathelicidin (CAMP gene product LL-37) and killing of intracellular Mycobacterium tuberculosis. Low serum 25-hydroxyvitamin D in African-American individuals correlates with failure to support cathelicidin mRNA induction, linking vitamin D status to TLR-mediated CAMP gene expression.","method":"TLR ligand stimulation of macrophages, RT-PCR for CAMP/VDR/CYP27B1, intracellular M. tuberculosis killing assay, serum 25-hydroxyvitamin D measurement and cathelicidin mRNA induction correlation","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — TLR→VDR→CAMP pathway established with functional antimicrobial readout; highly cited foundational paper","pmids":["16497887"],"is_preprint":false},{"year":2006,"finding":"Vitamin D (1,25-dihydroxyvitamin D3) triggers antimicrobial activity against intracellular M. tuberculosis in human THP-1 monocytes via induction of cathelicidin. siRNA knockdown of cathelicidin mRNA and protein expression completely inhibits 1,25D3-induced antimicrobial activity and leads to enhanced intracellular mycobacterial growth, demonstrating that cathelicidin is required for (not merely associated with) this pathway.","method":"siRNA knockdown, RT-PCR, Western blot, intracellular M. tuberculosis growth assay in THP-1 cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — causal requirement established by siRNA with direct infectious readout","pmids":["17675463"],"is_preprint":false},{"year":2006,"finding":"Cathelicidin (LL-37/CRAMP) is essential for urinary tract innate immunity. Epithelial cells of human and mouse urinary tract produce LL-37/hCAP-18 and CRAMP respectively upon bacterial contact. CRAMP-deficient mice and neutrophil-depleted mice show significantly impaired protection against E. coli urinary tract infection. Clinical E. coli strains more resistant to LL-37 cause more severe UTIs, establishing a causal antimicrobial role.","method":"In situ hybridization, immunohistochemistry, Western blot of urine, CRAMP-knockout mouse infection model, neutrophil depletion, clinical E. coli strain susceptibility comparison","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with in vivo infection model plus clinical correlation","pmids":["16751768"],"is_preprint":false},{"year":2006,"finding":"Kallikrein serine proteases (SCTE/kallikrein-5 and SCCE/kallikrein-7) in the stratum corneum control activation of hCAP18 to LL-37 and further processing to smaller cathelicidin peptides with distinct biological activities. SPINK5-deficient mice (lacking LEKTI serine protease inhibitor) show increased epidermal antimicrobial activity that is ablated by immunoabsorption of cathelicidin, demonstrating that the balance of protease activity at epithelial surfaces controls cathelicidin-mediated innate defense.","method":"Selective serine protease inhibitors, SELDI-TOF-MS, Western blot, siRNA for SCTE/SCCE, SPINK5-knockout mice, immunoabsorption of cathelicidin from epidermal extracts, antimicrobial assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 — specific processing enzymes identified by siRNA and inhibitors; confirmed in genetic mouse model","pmids":["17012259"],"is_preprint":false},{"year":2007,"finding":"LL-37 is the key factor mediating plasmacytoid dendritic cell (pDC) activation in psoriasis. LL-37 binds self-DNA to form aggregated, condensed structures that are delivered to and retained in early endocytic compartments of pDCs, where they trigger TLR9 to induce type I IFN production. This defines LL-37 as a factor that breaks innate tolerance to self-DNA.","method":"pDC stimulation assays, IFN-α ELISA, confocal microscopy of LL-37-DNA complex uptake into endosomes, TLR9 reporter assays, gel retardation assay for LL-37-DNA complex structure","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — mechanism (complex formation→endosomal delivery→TLR9 activation) established by multiple methods; widely cited foundational paper","pmids":["17873860"],"is_preprint":false},{"year":2007,"finding":"Rosacea skin shows abnormally high cathelicidin (CAMP gene product) levels and unique proteolytically processed cathelicidin peptide forms, resulting from increased stratum corneum tryptic enzyme (SCTE) activity in the epidermis. Injection of rosacea-specific cathelicidin peptides or SCTE into mouse skin increases inflammation. Targeted deletion of Camp in mice confirms that cathelicidin is required for SCTE-mediated skin inflammation.","method":"Immunohistochemistry, ELISA, mass spectrometry peptide identification, intradermal injection of peptides in mice, SCTE transgenic mice, Spink5-knockout mice, Camp-knockout mice","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout (Camp-null) confirms causal role; multiple in vivo models","pmids":["17676051"],"is_preprint":false},{"year":2007,"finding":"LL-37 binding selectivity between bacterial and host cell membranes is determined by lipid composition: LL-37 intercalates into anionic phospholipid-containing membranes (bacterial membranes) but shows strongly attenuated intercalation into membranes containing both cholesterol and sphingomyelin (characteristic of host cell outer leaflets). LL-37 may form cytotoxic oligomers similarly to amyloid-like peptides in the presence of anionic phospholipids.","method":"Minimum inhibitory concentration assay, dynamic light scattering, lipid monolayer penetration, fluorescence spectroscopy with Trp-containing LL-37 mutant (F27W)","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — biophysical characterization with functional MIC assay; single lab study","pmids":["18166145"],"is_preprint":false},{"year":2008,"finding":"The three-dimensional NMR structure of LL-37 in SDS and dioctanoylphosphatidylglycerol (D8PG) micelles reveals a curved amphipathic helix-bend-helix motif (residues 2–31) with a bend between Gly-14 and Glu-16, followed by a disordered C-terminal tail. Intermolecular NOE cross-peaks between aromatic residues (Phe-5, -6, -17, -27) and arginines with D8PG provide direct evidence for helix association with anionic lipid micelles. The minimal antibacterial peptide KR-12 (residues 18–29) forms a short amphipathic helix with selective toxicity toward bacteria.","method":"3D triple-resonance NMR spectroscopy of 13C,15N-labeled LL-37, intermolecular NOE measurements with D8PG micelles, synthetic peptide MIC assay, cytotoxicity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — high-resolution NMR structure with direct lipid-peptide interaction evidence and structure-activity delineation","pmids":["18818205"],"is_preprint":false},{"year":2008,"finding":"LL-37 increases TLR4 mRNA and protein levels in mast cells and induces release of IL-4, IL-5, and IL-1β. When LL-37 co-exists with LPS (TLR4 ligand), Th2 cytokine upregulation is cancelled but pro-inflammatory cytokine augmentation is maintained, demonstrating a switch of mast cell function toward innate immunity.","method":"RT-PCR, Western blot, ELISA for cytokines in mast cell (RBL-2H3) cultures treated with LL-37 ± LPS","journal":"Biological & pharmaceutical bulletin","confidence":"Medium","confidence_rationale":"Tier 3 — functional assay with mechanistic interpretation; single lab, single study","pmids":["18239275"],"is_preprint":false},{"year":2009,"finding":"LL-37 can bind self-RNA released by dying cells, protect it from extracellular degradation, and transport it into endosomal compartments of plasmacytoid DCs (pDCs) and myeloid DCs (mDCs). Self-RNA–LL-37 complexes activate TLR7 in pDCs (inducing IFN-α) and TLR8 in mDCs (inducing TNF-α/IL-6 and DC maturation). Self-RNA–LL-37 complexes are present in psoriatic skin lesions associated with mature mDCs in vivo.","method":"pDC and mDC stimulation assays, IFN-α/TNF-α ELISA, TLR blocking antibodies, TLR7/TLR8 reporter assays, RNA protection assay, immunohistochemistry of psoriatic skin","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — self-RNA transport and differential TLR7/TLR8 activation mechanism established with receptor-specific blocking; replicated","pmids":["19703986"],"is_preprint":false},{"year":2012,"finding":"LL-37 transports extracellular self-DNA into monocytes via a TLR-independent pathway. Once inside monocytes, self-DNA activates cytosolic DNA sensors requiring the adaptor protein STING and TBK1 kinase to induce type I IFNs. This activation is mediated by double-stranded B-form DNA regardless of sequence, CpG content, or methylation status.","method":"Type I IFN induction assay, pharmacological inhibitors of endosomal TLRs, siRNA knockdown of STING and TBK1, confocal microscopy of DNA uptake, synthetic DNA with varying CpG content/methylation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — STING/TBK1 pathway established by siRNA knockdown; mechanistic dissection with multiple DNA variants","pmids":["22927244"],"is_preprint":false},{"year":2012,"finding":"LL-37 and NETs activate the NLRP3 inflammasome in human and murine macrophages, causing caspase-1 activation and release of active IL-1β and IL-18. LL-37 activates NLRP3 via P2X7 receptor-mediated potassium efflux. This inflammasome activation is enhanced in lupus patient macrophages, and IL-18 in turn stimulates further NETosis, creating a feed-forward inflammatory loop.","method":"Caspase-1 activation assay, IL-1β/IL-18 ELISA, NLRP3 inflammasome inhibitors, P2X7 inhibitors, potassium efflux measurement, macrophages from lupus patients vs. controls, NETosis assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — P2X7/NLRP3 pathway mechanistically established with receptor inhibitors; validated in patient macrophages","pmids":["23267025"],"is_preprint":false},{"year":2014,"finding":"LL-37 is a T-cell autoantigen in psoriasis: CD4+ and/or CD8+ T cells specific for LL-37 are present in two-thirds of patients with moderate-to-severe plaque psoriasis, produce IFN-γ and Th17 cytokines, infiltrate lesional skin (tracked by MHC tetramer staining), and their prevalence correlates with disease activity.","method":"MHC-peptide tetramer staining, intracellular cytokine staining, flow cytometry, immunohistochemistry of lesional skin biopsies, correlation analysis with PASI score","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — tetramer-based T-cell identification is highly specific; LL-37 confirmed as adaptive immune autoantigen in patient cohort","pmids":["25470744"],"is_preprint":false},{"year":2015,"finding":"Commensal anaerobic bacteria (clostridial Firmicutes and Bacteroidetes) maintain C. albicans colonization resistance in mice by activating HIF-1α, which induces expression of the cathelicidin CRAMP (murine CAMP ortholog). Pharmacological HIF-1α activation induces CRAMP and reduces C. albicans colonization and mortality. In the presence of antibiotics, Hif1a and Camp (CRAMP) are required for Bacteroides thetaiotaomicron-induced protection.","method":"Antibiotic-treated and germ-free mouse models, pharmacological HIF-1α activators, Camp-knockout and Hif1a-knockout mice, C. albicans colonization quantification, survival analysis","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout (Camp-null) establishes causal requirement; HIF-1α→CAMP pathway confirmed in multiple models","pmids":["26053625"],"is_preprint":false},{"year":2016,"finding":"LL-37 and double-stranded RNA released from necrotic cells activate MAVS (mitochondrial antiviral-signaling protein) in keratinocytes, triggering a TBK1→AKT→IRF3 signaling cascade that leads to IFN-β production and dendritic cell maturation. MAVS-deficient mice show impaired epidermal IFN-β production by LL-37, and psoriatic/wounded human skin shows MAVS-associated IRF3 activation and IFN-β gene signatures.","method":"MAVS-knockout mice, siRNA knockdown of MAVS in keratinocytes, IFN-β ELISA, IRF3 phosphorylation assay, Western blot for TBK1/AKT/IRF3, immunohistochemistry of human psoriatic skin","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — complete signaling pathway (LL-37+dsRNA→MAVS→TBK1→AKT→IRF3→IFN-β) established by genetic and siRNA approaches","pmids":["27438769"],"is_preprint":false},{"year":2016,"finding":"Histone deacetylase inhibitor Entinostat up-regulates CAMP gene expression via a STAT3→HIF-1α transcriptional axis. Entinostat activates STAT3, which promotes HIF-1α expression; only HIF-1α (not STAT3) is directly recruited to the CAMP promoter. This was confirmed using shRNA knockdown and selective inhibitors, and in macrophages from a STAT3-mutant patient where Entinostat-elicited LL-37 expression was impaired.","method":"Luciferase reporter assay (CAMP promoter), shRNA knockdown of STAT3 and HIF-1α, selective inhibitors, ChIP assay showing HIF-1α recruitment to CAMP promoter, macrophages from STAT3-mutant patient","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — STAT3→HIF-1α→CAMP pathway established by ChIP, shRNA, inhibitors, and patient validation","pmids":["27633343"],"is_preprint":false},{"year":2018,"finding":"LL-37 activates platelets and enhances thrombus formation via formyl peptide receptor 2 (FPR2/ALX). LL-37 activates a range of platelet functions and shortens tail bleeding time in mice. Using a pharmacological FPR2/ALX inhibitor and Fpr2/3-deficient mice, platelet activation, thrombus formation, and hemostatic effects of LL-37 were abolished, establishing FPR2/ALX as the functional receptor.","method":"Platelet aggregation assay, thrombus formation assay (flow chamber), tail bleeding time in mice, pharmacological FPR2/ALX inhibitor, Fpr2/3-knockout mice","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus pharmacological inhibitor confirm FPR2/ALX as the platelet receptor; in vitro and in vivo","pmids":["30413433"],"is_preprint":false},{"year":2018,"finding":"MrgX2 (a G protein-coupled receptor) mediates LL-37 internalization and mast cell degranulation. LL-37 is rapidly internalized into LAD2 mast cells via clathrin-mediated endocytosis dependent on negatively charged sialic acid at the cell surface. siRNA knockdown of MrgX2 inhibits both LL-37 internalization and degranulation; MrgX2 overexpression enhances LL-37 internalization. Pertussis toxin (G-protein inhibitor) suppresses both processes. Internalized LL-37 co-localizes with MrgX2 in the perinuclear region.","method":"siRNA knockdown of MrgX2, stable MrgX2 overexpression in HMC-1 and HEK293 cells, clathrin endocytosis inhibitors (dynasore, chlorpromazine), pertussis toxin, neuraminidase treatment, β-hexosaminidase degranulation assay, confocal microscopy","journal":"Molecular medicine reports","confidence":"High","confidence_rationale":"Tier 2 — MrgX2 receptor established by siRNA knockdown and overexpression; endocytic pathway mechanistically dissected with multiple inhibitors","pmids":["30280189"],"is_preprint":false},{"year":2020,"finding":"Neutrophil extracellular trap (NET)-associated RNA (naRNA) in complex with LL-37 triggers a self-propagating inflammatory cycle in psoriasis. RNA (not canonical NET DNA) complexed with LL-37 activates TLR8/TLR13-mediated cytokine and NET release by primary murine and human neutrophils in vitro and in vivo. Transfer of NETs to naive human neutrophils prompts additional NET release.","method":"Primary murine and human PMN stimulation assays, TLR8 and TLR13 blocking/knockout, cytokine ELISA, NET quantification (MPO-DNA ELISA), in vivo neutrophil activation model, RNA vs. DNA complex comparison in psoriatic vs. normal skin","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — RNA-LL37 complex as TLR8/13 agonist established with receptor-specific knockouts/blockers; in vivo validation","pmids":["31913271"],"is_preprint":false},{"year":2021,"finding":"LL-37 and HMGB1 induce RAGE-dependent alveolar epithelial damage and impair lung tissue repair. Intranasal LL-37 and HMGB1 cause RAGE-dependent inflammation and alveolar tissue damage in mice within 6 h; RAGE-deficient mice are protected. RAGE inhibition reduces recovery from elastase-induced alveolar damage in precision-cut lung slices. In organoids, RAGE ligands reduce organoid-forming efficiency. siRNA knockdown of RAGE in A549 cells confirms RAGE's role in LL-37-induced impaired repair.","method":"RAGE-knockout mice, RAGE inhibitor (FPS-ZM1), siRNA knockdown in A549 cells, precision-cut lung slices (PCLS), lung organoids, intranasal instillation model, histology","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"High","confidence_rationale":"Tier 2 — RAGE as LL-37 receptor for alveolar damage established by genetic KO, pharmacological inhibition, and siRNA in multiple models","pmids":["34405719"],"is_preprint":false},{"year":2022,"finding":"LL-37 functions as a transporter of cyclic 2',3'-GMP-AMP (cGAMP) into target cells. LL-37 specifically binds cGAMP and delivers it intracellularly, activating robust STING-dependent interferon responses and host antiviral immunity. Vitamin D3 and sodium butyrate promote endogenous LL-37 expression and thereby enhance cGAMP-mediated immune responses. This identifies LL-37 as a cGAMP carrier bridging extracellular STING pathway activation.","method":"cGAMP-LL-37 binding assay, cell-based cGAMP delivery assay, IFN reporter assay, STING-knockout cells, antiviral immunity assay in vivo, LL-37 induction by vitamin D3/butyrate","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — cGAMP transport function established with STING-KO validation and binding assay; novel mechanistic role","pmids":["35649354"],"is_preprint":false},{"year":1993,"finding":"The C-terminal 37-amino acid domain of rabbit CAP18 (CAP18(106-142)) is the LPS-binding and antimicrobial domain, with broad bactericidal activity against Gram-positive and Gram-negative bacteria including S. aureus, S. pneumoniae, E. coli, P. aeruginosa, and S. typhimurium. Antimicrobial activity is highly dependent on peptide structure (helix integrity), and a 32-residue truncation from the C-terminus retains high activity while N-terminal truncation abolishes it. Unusually, CAP18(106-142) retains activity in serum.","method":"Synthetic peptide MIC assay against multiple bacterial strains, truncation variant activity comparison, serum stability assay","journal":"Antimicrobial agents and chemotherapy","confidence":"High","confidence_rationale":"Tier 1 — structure-activity relationship established with multiple truncation variants; widely cited foundational paper","pmids":["8109914"],"is_preprint":false},{"year":1994,"finding":"The primary antibacterial domain of rabbit CAP18 is a 21-residue cationic amphipathic alpha-helical sequence. Synthetic peptide has potent bactericidal activity against Gram-positive and Gram-negative bacteria and rapidly permeabilizes the E. coli inner membrane. Helix disruption (analogue synthesis) virtually eliminates antibacterial activity, while amphipathicity and the presence of an aromatic residue affect the kinetics of inner membrane permeabilization.","method":"Secondary structure prediction, synthetic peptide MIC assay, E. coli inner membrane permeabilization assay, synthesis of five analogues with helix-disrupting or amphipathicity-modifying substitutions","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — structure-function relationship established with mutagenesis analogues and membrane permeabilization assay","pmids":["8313956"],"is_preprint":false},{"year":1999,"finding":"Rabbit CAP18 interacts with the outer membrane of Gram-negative bacteria by adsorbing to lipopolysaccharide-containing leaflets and forming transient membrane lesions (ion-conducting pores). Electron microscopy shows outer membrane damage in sensitive E. coli but not resistant P. mirabilis R45. Voltage-clamp experiments on asymmetric planar bilayers show that CAP18 adsorbs to LPS-containing leaflets and forms transient current fluctuations (membrane lesions) at a lipid-specific clamp voltage, indicating voltage-dependent reorientation into a transmembrane configuration.","method":"Transmission electron microscopy of bacteria, voltage-clamp electrophysiology on planar asymmetric bilayer membranes with LPS or phospholipid leaflets","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — electrophysiological demonstration of membrane pore formation mechanism combined with electron microscopy","pmids":["10521271"],"is_preprint":false},{"year":2000,"finding":"Rabbit CAP18 intercalates into LPS-containing lipid matrices from sensitive bacterial strains but only weakly into LPS from resistant P. mirabilis R45 or negatively charged phospholipids, and not at all into neutral phosphatidylcholine. The L-Arap4N modification linked to the first Kdo residue of P. mirabilis R45 LPS is responsible for CAP18 resistance. The depth of intercalation is determined by structural differences in LPS, as shown by combined FRET, FTIR spectroscopy, and film balance measurements.","method":"Fluorescence resonance energy transfer (FRET), Fourier-transform infrared spectroscopy (FTIR), film balance (Langmuir trough) measurements on LPS/phospholipid monolayers and liposomes","journal":"The Journal of membrane biology","confidence":"High","confidence_rationale":"Tier 1 — mechanistic basis of LPS-resistance identified at molecular level using three orthogonal biophysical methods","pmids":["10931974"],"is_preprint":false}],"current_model":"CAMP encodes the human cathelicidin precursor hCAP-18, which is processed extracellularly by proteinase 3 to release the active 37-residue LL-37 peptide; LL-37 exerts broad antimicrobial activity by forming toroidal pores in anionic bacterial membranes via an amphipathic alpha-helical structure (NMR-determined), binds LPS to neutralize TLR4 signaling (reducing NF-κB activation), acts as a chemoattractant for neutrophils, monocytes, and T cells via FPRL1/FPR2, activates the P2X7 receptor and NLRP3 inflammasome for IL-1β release, transports self-DNA and self-RNA into endosomal compartments of dendritic cells to activate TLR7/TLR8/TLR9, delivers cGAMP intracellularly to activate STING-dependent antiviral immunity, promotes angiogenesis and wound re-epithelialization via FPRL1 on endothelial cells, activates platelet aggregation and thrombus formation via FPR2/ALX, induces IFN-β in keratinocytes through MAVS–TBK1–AKT–IRF3 signaling, and is transcriptionally regulated by vitamin D (via VDR), by TLRs (via VDR/CYP27B1 induction), by HIF-1α (recruited to the CAMP promoter downstream of STAT3 activation), and post-translationally processed in skin by kallikrein serine proteases (SCTE/SCCE) to generate peptide variants with distinct activities."},"narrative":{"teleology":[{"year":1993,"claim":"Identification of the C-terminal domain of CAP18 as the minimal LPS-binding and bactericidal module established that cathelicidins concentrate antimicrobial function in a short cationic α-helical segment whose integrity is essential for activity.","evidence":"Synthetic truncation variants tested in MIC assays against multiple bacterial species, with serum stability evaluation (rabbit CAP18)","pmids":["8109914","8313956"],"confidence":"High","gaps":["Human LL-37 peptide not yet identified","Processing enzyme in vivo unknown","Mechanism of membrane killing unresolved"]},{"year":1995,"claim":"Cloning of the human CAMP gene revealed that LL-37 is the only human cathelicidin, with broad-spectrum antibacterial activity and LPS-neutralizing capacity that protects against endotoxemia in vivo, establishing a dual antimicrobial and anti-inflammatory role.","evidence":"cDNA cloning from bone marrow, synthetic LL-37 antimicrobial assays, LPS-binding assays, mouse endotoxemia survival model","pmids":["7529412","7890387","7649303"],"confidence":"High","gaps":["In vivo processing enzyme unknown","Mechanism of LPS neutralization at receptor level unresolved","NMR structure of human LL-37 not yet determined"]},{"year":1996,"claim":"Complete genomic characterization placed CAMP at 3p21.3 with four exons and defined its granulocyte-restricted expression during myeloid differentiation, revealing that transcription peaks at the myelocyte stage while protein accumulates through terminal neutrophil maturation.","evidence":"FISH mapping, somatic cell hybrid PCR, Northern/Western blot of bone marrow differentiation stages, immunohistochemistry","pmids":["8681941","8946956","9850169"],"confidence":"High","gaps":["Regulation of transcription beyond myeloid commitment unknown","Post-transcriptional storage mechanism not characterized"]},{"year":1998,"claim":"Structure-activity studies demonstrated that LL-37's antibacterial potency depends on anion-induced cooperative α-helical oligomerization, and identification of apolipoprotein A-I as a plasma scavenger explained why serum attenuates LL-37 activity.","evidence":"CD spectroscopy with anion titrations, MIC assays, affinity chromatography, SPR binding kinetics, anti-apoA-I blocking antibody","pmids":["9452503","9837875"],"confidence":"High","gaps":["Oligomeric state and stoichiometry on bacterial membranes unknown","In vivo relevance of apoA-I scavenging during infection unresolved"]},{"year":2000,"claim":"Discovery that LL-37 is chemotactic for monocytes, neutrophils, and T cells via FPRL1/FPR2 receptor transformed understanding of cathelicidin from a simple antimicrobial to an immune cell recruiter bridging innate and adaptive immunity.","evidence":"Chemotaxis assays, Ca²⁺ mobilization in FPRL1-transfected HEK293 cells, cross-desensitization with FPRL1-specific agonists, expression in NK cells, γδ T cells, monocytes","pmids":["11015447","11049988"],"confidence":"High","gaps":["Downstream FPRL1 signaling cascade not mapped","Relative contribution of chemotaxis vs. antimicrobial activity in vivo unknown"]},{"year":2001,"claim":"Identification of proteinase 3 as the specific extracellular processing enzyme for hCAP-18→LL-37 after neutrophil degranulation, combined with the mechanism of LPS neutralization via competitive blockade of LBP–CD14 interaction, defined the activation and anti-endotoxin pathways.","evidence":"Immunoelectron microscopy, selective protease inhibitor panel, LPS–CD14 binding competition, in vivo endotoxin model","pmids":["11389039","11544322"],"confidence":"High","gaps":["Tissue-specific processing enzymes outside neutrophils unknown","Kinetics of proteinase 3 cleavage at infection sites not determined"]},{"year":2003,"claim":"LL-37 was shown to form toroidal pores in bacterial membranes (not barrel-stave or detergent-like), to promote angiogenesis and wound re-epithelialization via FPRL1 on endothelial cells, and to be required for skin repair—expanding its role from antimicrobial defense to tissue regeneration.","evidence":"Solid-state ¹⁵N/³¹P NMR in oriented bilayers, CAM angiogenesis assay, CRAMP-knockout mouse wound model, ex vivo human wound model with anti-LL-37 blocking antibody","pmids":["12767238","12782669","12603850"],"confidence":"High","gaps":["Pore size and stoichiometry not resolved","Signaling pathway downstream of FPRL1 in endothelial cells not elucidated"]},{"year":2004,"claim":"LL-37 was found to directly activate the P2X7 receptor on monocytes to trigger caspase-1 and IL-1β release independently of autocrine ATP, establishing it as an endogenous danger signal coupling antimicrobial peptide release to inflammasome activation.","evidence":"P2X7 pharmacological inhibitors (oxidized ATP, KN04, KN62), apyrase control, IL-1β ELISA, caspase-1 assay in LPS-primed monocytes","pmids":["15067080"],"confidence":"High","gaps":["Direct biophysical interaction between LL-37 and P2X7 not demonstrated","NLRP3 involvement not yet tested"]},{"year":2006,"claim":"A TLR2/1→VDR→CYP27B1→vitamin D→CAMP transcriptional axis was discovered in macrophages, causally linking vitamin D sufficiency to cathelicidin-dependent killing of intracellular M. tuberculosis; concurrently, CRAMP-knockout mice revealed cathelicidin's essential role in urinary tract defense, and kallikrein proteases were identified as skin-specific processing enzymes generating diverse cathelicidin peptide forms.","evidence":"TLR-stimulated macrophages with vitamin D measurements, siRNA knockdown of CAMP abolishing mycobacterial killing, CRAMP-KO UTI model, SCTE/SCCE siRNA and SPINK5-KO mice for skin processing","pmids":["16497887","17675463","16751768","17012259"],"confidence":"High","gaps":["VDR binding site in CAMP promoter not mapped at nucleotide resolution in this work","Clinical vitamin D supplementation efficacy for TB unproven"]},{"year":2007,"claim":"LL-37 was discovered to break innate tolerance to self-DNA by condensing extracellular DNA into aggregates that resist degradation, delivering them into early endosomes of plasmacytoid DCs to activate TLR9 and drive type I IFN—establishing the mechanism for LL-37-mediated autoimmune amplification in psoriasis and linking aberrant cathelicidin processing to rosacea pathogenesis.","evidence":"pDC IFN-α assays, TLR9 reporter, confocal microscopy of LL-37–DNA endosomal uptake, gel retardation; Camp-KO mice for rosacea; MHC tetramer identification of LL-37-specific T cells in psoriasis patients","pmids":["17873860","17676051"],"confidence":"High","gaps":["Structural basis of LL-37–DNA condensation unknown","Why some individuals develop autoimmune responses to LL-37 while others do not is unresolved"]},{"year":2008,"claim":"The three-dimensional NMR structure of LL-37 in lipid micelles revealed a curved helix-bend-helix amphipathic architecture with direct lipid contacts via aromatic and cationic residues, and defined KR-12 (residues 18–29) as the minimal bactericidal core—providing the first atomic-resolution template for the human cathelicidin.","evidence":"3D triple-resonance NMR of ¹³C,¹⁵N-labeled LL-37, intermolecular NOEs with D8PG micelles, MIC assays of KR-12","pmids":["18818205"],"confidence":"High","gaps":["No crystal structure of LL-37 in a membrane bilayer context","Oligomeric pore structure not resolved"]},{"year":2009,"claim":"Extension of the nucleic acid transport paradigm to self-RNA showed that LL-37–RNA complexes differentially activate TLR7 in pDCs and TLR8 in mDCs, broadening the mechanism of innate tolerance breaking beyond DNA to include RNA sensing.","evidence":"pDC/mDC stimulation assays, IFN-α/TNF-α ELISA, TLR7/TLR8 blocking antibodies and reporter assays, RNA protection assay, immunohistochemistry of psoriatic skin","pmids":["19703986"],"confidence":"High","gaps":["Structural determinants governing LL-37 preference for RNA vs. DNA unknown","Relative contribution of TLR7 vs. TLR8 pathway in psoriasis not quantified"]},{"year":2012,"claim":"Two cytosolic sensing pathways were linked to LL-37: transport of self-DNA into monocytes activates the STING–TBK1 axis for type I IFN (TLR-independent), and LL-37 activates P2X7-dependent K⁺ efflux to trigger the NLRP3 inflammasome in macrophages, creating a feedforward loop with NETosis in lupus.","evidence":"siRNA knockdown of STING and TBK1, NLRP3 inhibitors, P2X7 inhibitors, potassium efflux measurement, lupus patient macrophages","pmids":["22927244","23267025"],"confidence":"High","gaps":["How LL-37 escapes endosomes to deliver DNA to cytosolic STING unknown","Therapeutic targetability of the NET–LL-37–NLRP3 loop not tested"]},{"year":2014,"claim":"LL-37 was identified as a T-cell autoantigen in psoriasis, with LL-37-specific CD4⁺/CD8⁺ T cells infiltrating lesional skin and correlating with disease severity, definitively linking cathelicidin to adaptive autoimmunity.","evidence":"MHC-peptide tetramer staining, intracellular cytokine profiling, flow cytometry, skin biopsy immunohistochemistry, PASI correlation","pmids":["25470744"],"confidence":"High","gaps":["HLA restriction elements for all LL-37 epitopes not fully defined","Whether LL-37-specific T cells are pathogenic drivers or bystanders not formally proven"]},{"year":2016,"claim":"Transcriptional regulation of CAMP was extended to a STAT3→HIF-1α axis (HIF-1α directly recruited to the CAMP promoter), and LL-37 was shown to activate MAVS→TBK1→AKT→IRF3→IFN-β signaling in keratinocytes when complexed with dsRNA, linking cathelicidin to cytosolic antiviral sensing beyond TLR pathways.","evidence":"ChIP showing HIF-1α at CAMP promoter, shRNA/inhibitor knockdowns, STAT3-mutant patient macrophages; MAVS-KO mice, siRNA in keratinocytes, psoriatic skin IFN-β gene signatures","pmids":["27633343","27438769"],"confidence":"High","gaps":["Whether HIF-1α and VDR cooperate or act independently at the CAMP promoter not resolved","Relative contribution of MAVS vs. TLR pathways in skin inflammation not quantified"]},{"year":2018,"claim":"LL-37's receptor repertoire was expanded to include FPR2/ALX on platelets (mediating thrombus formation, confirmed in Fpr2/3-KO mice) and MrgX2 on mast cells (mediating degranulation via clathrin-dependent endocytosis), establishing LL-37 as a multi-receptor signaling ligand in hemostasis and allergy.","evidence":"FPR2/ALX inhibitor + Fpr2/3-KO mice for platelet aggregation/bleeding time; MrgX2 siRNA/overexpression, endocytosis inhibitors, confocal co-localization in mast cells","pmids":["30413433","30280189"],"confidence":"High","gaps":["Structural basis of LL-37 promiscuity across GPCRs (FPRL1, FPR2, MrgX2) unknown","In vivo relevance of mast cell MrgX2 activation by LL-37 in disease settings not established"]},{"year":2022,"claim":"Discovery that LL-37 binds and transports cGAMP intracellularly to activate STING-dependent antiviral immunity added a cell-extrinsic second messenger delivery function, positioning cathelicidin as a carrier that bridges extracellular danger signals to cytosolic innate sensors.","evidence":"cGAMP-LL-37 binding assay, STING-KO cell IFN reporter, antiviral assay in vivo, LL-37 induction by vitamin D3/butyrate","pmids":["35649354"],"confidence":"High","gaps":["Stoichiometry and affinity of cGAMP–LL-37 complex not determined","Whether other cathelicidins share cGAMP transport capacity unknown","Endosomal escape mechanism for cGAMP delivery to cytosolic STING not resolved"]},{"year":null,"claim":"Key unresolved questions include the atomic structure of the LL-37 oligomeric pore in a membrane bilayer, the mechanism by which LL-37-cargo complexes escape endosomes to access cytosolic sensors (STING, MAVS), and whether the multiple receptor interactions (FPRL1, FPR2, P2X7, MrgX2, RAGE) operate cooperatively or in cell-type-specific isolation during infection and autoimmunity.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of LL-37 pore in a bilayer","Endosomal escape mechanism unknown","Integrated signaling model across multiple receptors lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0090729","term_label":"toxin activity","supporting_discovery_ids":[0,1,6,40,41]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[4,16,25,26,43]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[9,14,35]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[23,28,29,39]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[12,13,17,30]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,7,11,22]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[23,28,36]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,11]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,10,13,17,19,20,23,28,29,30,33,37,39]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,14,17,29,30,33,34,35,38]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[23,24,28,31,37,38]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[35]}],"complexes":[],"partners":["FPR2","P2X7R","MRGPRX2","AGER","PRTN3","KLK5","KLK7","APOA1"],"other_free_text":[]},"mechanistic_narrative":"CAMP encodes the sole human cathelicidin, hCAP-18, which is processed extracellularly by proteinase 3 in neutrophils—and by kallikrein serine proteases (KLK5/KLK7) in skin—to release the amphipathic α-helical peptide LL-37 that kills bacteria by forming toroidal pores in anionic membranes [PMID:11389039, PMID:12767238, PMID:17012259]. Beyond direct antimicrobial activity, LL-37 functions as a multifaceted immunomodulator: it neutralizes LPS by competing with LBP for CD14 binding, recruits leukocytes via FPRL1/FPR2, activates the P2X7–NLRP3 inflammasome axis for IL-1β release, transports self-DNA and self-RNA into endosomes to trigger TLR7/TLR8/TLR9-mediated type I interferon production, delivers cGAMP intracellularly to activate STING-dependent antiviral responses, and promotes angiogenesis and wound re-epithelialization through FPRL1 on endothelial cells [PMID:11015447, PMID:12244186, PMID:23267025, PMID:17873860, PMID:19703986, PMID:35649354, PMID:12782669]. CAMP transcription is induced by vitamin D via VDR downstream of TLR2/1 signaling and by HIF-1α recruited to the CAMP promoter through STAT3, linking innate immune sensing and metabolic cues to cathelicidin-dependent host defense against pathogens including Mycobacterium tuberculosis and uropathogenic E. coli [PMID:16497887, PMID:27633343, PMID:16751768]. LL-37 also breaks innate tolerance to self-nucleic acids—serving as an autoantigen recognized by T cells in psoriasis—and drives pathological inflammation in psoriasis and rosacea through aberrant protease processing and TLR activation [PMID:25470744, PMID:17676051, PMID:31913271]."},"prefetch_data":{"uniprot":{"accession":"P49913","full_name":"Cathelicidin antimicrobial peptide","aliases":["18 kDa cationic antimicrobial protein","CAP-18","hCAP-18"],"length_aa":170,"mass_kda":19.3,"function":"Antimicrobial protein that is an integral component of the innate immune system (PubMed:14978112, PubMed:16637646, PubMed:18818205, PubMed:22879591, PubMed:9736536). Binds to bacterial lipopolysaccharides (LPS) (PubMed:16637646, PubMed:18818205). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed:22879591). Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin (PubMed:14978112). The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) (PubMed:9736536) Antimicrobial peptide that is an integral component of the innate immune system (PubMed:10417311, PubMed:15778390, PubMed:16637646, PubMed:18818205, PubMed:22879591, PubMed:32753597, PubMed:33060695, PubMed:34708076, PubMed:8681941, PubMed:9736536). Binds to bacterial lipopolysaccharides (LPS) (PubMed:10417311, PubMed:16637646, PubMed:18818205, PubMed:33060695, PubMed:9736536). Causes membrane permeabilization by forming transmembrane pores (in vitro) (PubMed:22879591, PubMed:32753597, PubMed:33060695). Causes lysis of E.coli (PubMed:10417311). Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) (PubMed:10417311, PubMed:32753597, PubMed:8681941, PubMed:9736536). Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) (PubMed:9736536). Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation (PubMed:34708076). May form supramolecular fiber-like assemblies on bacterial membranes (PubMed:29133814). Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes (PubMed:15778390). Exhibits hemolytic activity against red blood cells (PubMed:10417311) Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro) Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112) Poorly active (MIC > 150 uM) against E.coli strain K12 (PubMed:14978112). Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 (PubMed:14978112) Moderately antibacterial Moderately antibacterial (PubMed:14978112). Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112) Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition (PubMed:14978112). Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes (PubMed:14978112) Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells","subcellular_location":"Secreted; Vesicle","url":"https://www.uniprot.org/uniprotkb/P49913/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CAMP","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CAMP","total_profiled":1310},"omim":[{"mim_id":"621459","title":"TRANSMEMBRANE PROTEIN 217; TMEM217","url":"https://www.omim.org/entry/621459"},{"mim_id":"621444","title":"TBC1 DOMAIN FAMILY, MEMBER 31; TBC1D31","url":"https://www.omim.org/entry/621444"},{"mim_id":"621367","title":"CARDIAC CONDUCTION DISEASE WITH OR WITHOUT CARDIOMYOPATHY 2; CCCM2","url":"https://www.omim.org/entry/621367"},{"mim_id":"621336","title":"SHORT SLEEP, FAMILIAL NATURAL, 3; FNSS3","url":"https://www.omim.org/entry/621336"},{"mim_id":"621174","title":"CHOLESIN; CHLSN","url":"https://www.omim.org/entry/621174"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":2752.0}],"url":"https://www.proteinatlas.org/search/CAMP"},"hgnc":{"alias_symbol":["CAP18","FALL39","FALL-39","LL37"],"prev_symbol":[]},"alphafold":{"accession":"P49913","domains":[{"cath_id":"3.10.450.10","chopping":"34-133","consensus_level":"high","plddt":90.2997,"start":34,"end":133}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49913","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49913-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49913-F1-predicted_aligned_error_v6.png","plddt_mean":80.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CAMP","jax_strain_url":"https://www.jax.org/strain/search?query=CAMP"},"sequence":{"accession":"P49913","fasta_url":"https://rest.uniprot.org/uniprotkb/P49913.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49913/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49913"}},"corpus_meta":[{"pmid":"8681941","id":"PMC_8681941","title":"The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes.","date":"1996","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8681941","citation_count":450,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7890387","id":"PMC_7890387","title":"Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein.","date":"1995","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7890387","citation_count":444,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17084085","id":"PMC_17084085","title":"Epac proteins: multi-purpose cAMP targets.","date":"2006","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17084085","citation_count":436,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25470744","id":"PMC_25470744","title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25470744","citation_count":419,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15545605","id":"PMC_15545605","title":"Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15545605","citation_count":400,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11056535","id":"PMC_11056535","title":"cAMP-GEFII is a direct target of cAMP in regulated exocytosis.","date":"2000","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11056535","citation_count":387,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19864144","id":"PMC_19864144","title":"Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown.","date":"2009","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19864144","citation_count":348,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8689562","id":"PMC_8689562","title":"Transcription factors responsive to cAMP.","date":"1995","source":"Annual review of cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8689562","citation_count":315,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19068548","id":"PMC_19068548","title":"The roles of cathelicidin LL-37 in immune defences and novel clinical applications.","date":"2009","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19068548","citation_count":222,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31913271","id":"PMC_31913271","title":"Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31913271","citation_count":211,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11544322","id":"PMC_11544322","title":"Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11544322","citation_count":206,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21693141","id":"PMC_21693141","title":"Wound healing activity of the human antimicrobial peptide LL37.","date":"2011","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/21693141","citation_count":199,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12819054","id":"PMC_12819054","title":"Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes.","date":"2003","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12819054","citation_count":184,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25271346","id":"PMC_25271346","title":"Endosomal generation of cAMP in GPCR signaling.","date":"2014","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/25271346","citation_count":180,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21412271","id":"PMC_21412271","title":"FRET measurements of intracellular cAMP concentrations and cAMP analog permeability in intact cells.","date":"2011","source":"Nature protocols","url":"https://pubmed.ncbi.nlm.nih.gov/21412271","citation_count":177,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25173841","id":"PMC_25173841","title":"PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing.","date":"2014","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/25173841","citation_count":176,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6088478","id":"PMC_6088478","title":"Competitive cAMP antagonists for cAMP-receptor proteins.","date":"1984","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6088478","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27438769","id":"PMC_27438769","title":"Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27438769","citation_count":148,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22927244","id":"PMC_22927244","title":"Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22927244","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2554303","id":"PMC_2554303","title":"The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2554303","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23636265","id":"PMC_23636265","title":"cAMP and mitochondria.","date":"2013","source":"Physiology (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23636265","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9837875","id":"PMC_9837875","title":"Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9837875","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1883348","id":"PMC_1883348","title":"Complementary DNA sequence of rabbit CAP18--a unique lipopolysaccharide binding protein.","date":"1991","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1883348","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6086345","id":"PMC_6086345","title":"Inhibitory action of certain cyclophosphate derivatives of cAMP on cAMP-dependent protein kinases.","date":"1984","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6086345","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32509872","id":"PMC_32509872","title":"Significance of LL-37 on Immunomodulation and Disease Outcome.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32509872","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15279899","id":"PMC_15279899","title":"C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15279899","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18166145","id":"PMC_18166145","title":"Binding of LL-37 to model biomembranes: insight into target vs host cell recognition.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18166145","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12768543","id":"PMC_12768543","title":"Mechanism of action of ACTH: beyond cAMP.","date":"2003","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/12768543","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33932338","id":"PMC_33932338","title":"Vertebrate cells differentially interpret ciliary and extraciliary cAMP.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33932338","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3539674","id":"PMC_3539674","title":"Phosphorylation of purified insulin receptor by cAMP kinase.","date":"1987","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/3539674","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25017568","id":"PMC_25017568","title":"Cyclic AMP (cAMP) signaling in melanocytes and melanoma.","date":"2014","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/25017568","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27233501","id":"PMC_27233501","title":"Mitochondrial cAMP signaling.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27233501","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9573062","id":"PMC_9573062","title":"Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia.","date":"1998","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9573062","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27357676","id":"PMC_27357676","title":"Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27357676","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15661923","id":"PMC_15661923","title":"Expression and activity of beta-defensins and LL-37 in the developing human lung.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15661923","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26434733","id":"PMC_26434733","title":"Unique features of human cathelicidin LL-37.","date":"2015","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26434733","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8313956","id":"PMC_8313956","title":"Identification and characterization of a primary antibacterial domain in CAP18, a lipopolysaccharide binding protein from rabbit leukocytes.","date":"1994","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8313956","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29753132","id":"PMC_29753132","title":"Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37.","date":"2018","source":"International journal of antimicrobial agents","url":"https://pubmed.ncbi.nlm.nih.gov/29753132","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16246108","id":"PMC_16246108","title":"Compartmentalization of adenylate cyclase and cAMP signalling.","date":"2005","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/16246108","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1667580","id":"PMC_1667580","title":"Transcriptional regulation by cAMP.","date":"1991","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1667580","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8109914","id":"PMC_8109914","title":"Antimicrobial activity of rabbit CAP18-derived peptides.","date":"1993","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/8109914","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19801686","id":"PMC_19801686","title":"Extracellular 2',3'-cAMP is a source of adenosine.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19801686","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35649354","id":"PMC_35649354","title":"LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35649354","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12952077","id":"PMC_12952077","title":"cAMP signaling in Dictyostelium. Complexity of cAMP synthesis, degradation and detection.","date":"2002","source":"Journal of muscle research and cell motility","url":"https://pubmed.ncbi.nlm.nih.gov/12952077","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29385021","id":"PMC_29385021","title":"PDE4-Mediated cAMP Signalling.","date":"2018","source":"Journal of cardiovascular development and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29385021","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8132348","id":"PMC_8132348","title":"Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity.","date":"1994","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8132348","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26795432","id":"PMC_26795432","title":"Mechanisms Restricting Diffusion of Intracellular cAMP.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26795432","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20042575","id":"PMC_20042575","title":"LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20042575","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23895508","id":"PMC_23895508","title":"CFTR: a hub for kinases and crosstalk of cAMP and Ca2+.","date":"2013","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/23895508","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10854692","id":"PMC_10854692","title":"What is a cAMP response unit?","date":"2000","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10854692","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15645239","id":"PMC_15645239","title":"Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats.","date":"2005","source":"Pediatric surgery international","url":"https://pubmed.ncbi.nlm.nih.gov/15645239","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9373334","id":"PMC_9373334","title":"Anti-microbial activity of human CAP18 peptides.","date":"1995","source":"Immunotechnology : an international journal of immunological engineering","url":"https://pubmed.ncbi.nlm.nih.gov/9373334","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7649303","id":"PMC_7649303","title":"The solution structure of the active domain of CAP18--a lipopolysaccharide binding protein from rabbit leukocytes.","date":"1995","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7649303","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32923608","id":"PMC_32923608","title":"Topical nanoparticles interfering with the DNA-LL37 complex to alleviate psoriatic inflammation in mice and monkeys.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32923608","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22005071","id":"PMC_22005071","title":"Antimicrobial and antibiofilm activity of LL-37 and its truncated variants against Burkholderia pseudomallei.","date":"2011","source":"International journal of antimicrobial agents","url":"https://pubmed.ncbi.nlm.nih.gov/22005071","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29618637","id":"PMC_29618637","title":"Interaction of 2',3'-cAMP with Rbp47b Plays a Role in Stress Granule Formation.","date":"2018","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29618637","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8946956","id":"PMC_8946956","title":"Structural, functional analysis and localization of the human CAP18 gene.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8946956","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24450633","id":"PMC_24450633","title":"cAMP signalling in the vasculature: the role of Epac (exchange protein directly activated by cAMP).","date":"2014","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/24450633","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18239275","id":"PMC_18239275","title":"Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity.","date":"2008","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/18239275","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11832418","id":"PMC_11832418","title":"Extracellular cAMP inhibits proximal reabsorption: are plasma membrane cAMP receptors involved?","date":"2002","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11832418","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22371403","id":"PMC_22371403","title":"[Regulation of melanogenesis: the role of cAMP and MITF].","date":"2012","source":"Postepy higieny i medycyny doswiadczalnej (Online)","url":"https://pubmed.ncbi.nlm.nih.gov/22371403","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9835525","id":"PMC_9835525","title":"Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model.","date":"1998","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/9835525","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22250708","id":"PMC_22250708","title":"Role of defensins and cathelicidin LL37 in auto-immune and auto-inflammatory diseases.","date":"2012","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22250708","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38540740","id":"PMC_38540740","title":"LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38540740","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35698353","id":"PMC_35698353","title":"Delivery LL37 by chitosan nanoparticles for enhanced antibacterial and antibiofilm efficacy.","date":"2022","source":"Carbohydrate polymers","url":"https://pubmed.ncbi.nlm.nih.gov/35698353","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30413433","id":"PMC_30413433","title":"The endogenous antimicrobial cathelicidin LL37 induces platelet activation and augments thrombus formation.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30413433","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30842778","id":"PMC_30842778","title":"LL37 Inhibits Aspergillus fumigatus Infection via Directly Binding to the Fungus and Preventing Excessive Inflammation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30842778","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27633343","id":"PMC_27633343","title":"Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1α transcription factors.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27633343","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8536804","id":"PMC_8536804","title":"Dual role of cAMP during Dictyostelium development.","date":"1995","source":"Experientia","url":"https://pubmed.ncbi.nlm.nih.gov/8536804","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25672949","id":"PMC_25672949","title":"Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile.","date":"2015","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25672949","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22963560","id":"PMC_22963560","title":"Interactions between calcium and cAMP signaling.","date":"2012","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22963560","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11108131","id":"PMC_11108131","title":"Transcriptional regulation by cAMP in the heart.","date":"2000","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11108131","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25197165","id":"PMC_25197165","title":"Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25197165","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2169573","id":"PMC_2169573","title":"Characteristics of the cAMP response unit.","date":"1990","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/2169573","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35989245","id":"PMC_35989245","title":"The adipocyte supersystem of insulin and cAMP signaling.","date":"2022","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35989245","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38310024","id":"PMC_38310024","title":"cAMP signaling: a remarkably regional affair.","date":"2024","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38310024","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15633459","id":"PMC_15633459","title":"Involvement of cAMP in neuronal survival and axonal regeneration.","date":"2004","source":"Anatomical science international","url":"https://pubmed.ncbi.nlm.nih.gov/15633459","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24281338","id":"PMC_24281338","title":"Multiple facets of cAMP signalling and physiological impact: cAMP compartmentalization in the lung.","date":"2012","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/24281338","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9850169","id":"PMC_9850169","title":"Evaluation of the expression of human CAP18 gene during neutrophil maturation in the bone marrow.","date":"1998","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9850169","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20631411","id":"PMC_20631411","title":"Regulation of cAMP by phosphodiesterases in erythrocytes.","date":"2010","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/20631411","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32777162","id":"PMC_32777162","title":"Cyclic adenosine monophosphate (cAMP) signaling in melanocyte pigmentation and melanomagenesis.","date":"2020","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/32777162","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8643446","id":"PMC_8643446","title":"Single cell Ca2+/cAMP cross-talk monitored by simultaneous Ca2+/cAMP fluorescence ratio imaging.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8643446","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19013136","id":"PMC_19013136","title":"Role of cAMP in mediating AHR signaling.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19013136","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26721674","id":"PMC_26721674","title":"Discovery and Roles of 2',3'-cAMP in Biological Systems.","date":"2017","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26721674","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35954305","id":"PMC_35954305","title":"LL-37, a Multi-Faceted Amphipathic Peptide Involved in NETosis.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35954305","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35043968","id":"PMC_35043968","title":"2',3'-cAMP treatment mimics the stress molecular response in Arabidopsis thaliana.","date":"2022","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35043968","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21916808","id":"PMC_21916808","title":"cAMP during HIV infection: friend or foe?","date":"2011","source":"AIDS research and human retroviruses","url":"https://pubmed.ncbi.nlm.nih.gov/21916808","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30537236","id":"PMC_30537236","title":"LL-37 and its analog FF/CAP18 attenuate neutrophil migration in sepsis-induced acute lung injury.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30537236","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12012389","id":"PMC_12012389","title":"cAMP pathway in podocytes.","date":"2002","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/12012389","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26388770","id":"PMC_26388770","title":"A dynamic interface between ubiquitylation and cAMP signaling.","date":"2015","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26388770","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16524641","id":"PMC_16524641","title":"Anchored cAMP signaling: onward and upward - a short history of compartmentalized cAMP signal transduction.","date":"2006","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16524641","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10931974","id":"PMC_10931974","title":"Mechanisms of action of rabbit CAP18 on monolayers and liposomes made from endotoxins or phospholipids.","date":"2000","source":"The Journal of membrane biology","url":"https://pubmed.ncbi.nlm.nih.gov/10931974","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10521271","id":"PMC_10521271","title":"Molecular mechanisms of interaction of rabbit CAP18 with outer membranes of gram-negative bacteria.","date":"1999","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10521271","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12930528","id":"PMC_12930528","title":"Sensitivity of genera Porphyromonas and Prevotella to the bactericidal action of C-terminal domain of human CAP18 and its analogues.","date":"2003","source":"Oral microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12930528","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7778029","id":"PMC_7778029","title":"Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs.","date":"1995","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/7778029","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33994918","id":"PMC_33994918","title":"NETs Lead to Sympathetic Hyperactivity After Traumatic Brain Injury Through the LL37-Hippo/MST1 Pathway.","date":"2021","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33994918","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34405719","id":"PMC_34405719","title":"LL-37 and HMGB1 induce alveolar damage and reduce lung tissue regeneration via RAGE.","date":"2021","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34405719","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10706821","id":"PMC_10706821","title":"Dictyostelium development-socializing through cAMP.","date":"1999","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10706821","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30280189","id":"PMC_30280189","title":"MrgX2‑mediated internalization of LL‑37 and degranulation of human LAD2 mast cells.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30280189","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34365796","id":"PMC_34365796","title":"Macropinocytosis-Inducible Extracellular Vesicles Modified with Antimicrobial Protein CAP18-Derived Cell-Penetrating Peptides for Efficient Intracellular Delivery.","date":"2021","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/34365796","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16497887","id":"PMC_16497887","title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.","date":"2006","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16497887","citation_count":2801,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17873860","id":"PMC_17873860","title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17873860","citation_count":1414,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11015447","id":"PMC_11015447","title":"LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11015447","citation_count":923,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20209079","id":"PMC_20209079","title":"The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20209079","citation_count":846,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12782669","id":"PMC_12782669","title":"An angiogenic role for the human peptide antibiotic LL-37/hCAP-18.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12782669","citation_count":706,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11389039","id":"PMC_11389039","title":"Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11389039","citation_count":672,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17676051","id":"PMC_17676051","title":"Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17676051","citation_count":638,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9182550","id":"PMC_9182550","title":"The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9182550","citation_count":617,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17675463","id":"PMC_17675463","title":"Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17675463","citation_count":615,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11049988","id":"PMC_11049988","title":"The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11049988","citation_count":602,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19703986","id":"PMC_19703986","title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8.","date":"2009","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19703986","citation_count":578,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9689116","id":"PMC_9689116","title":"The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9689116","citation_count":569,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12244186","id":"PMC_12244186","title":"The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12244186","citation_count":557,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9452503","id":"PMC_9452503","title":"Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9452503","citation_count":521,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16751768","id":"PMC_16751768","title":"The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16751768","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16456005","id":"PMC_16456005","title":"Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16456005","citation_count":444,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23246832","id":"PMC_23246832","title":"A comprehensive summary of LL-37, the factotum human cathelicidin peptide.","date":"2012","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23246832","citation_count":440,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12603850","id":"PMC_12603850","title":"The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium.","date":"2003","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12603850","citation_count":435,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23267025","id":"PMC_23267025","title":"Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23267025","citation_count":418,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12767238","id":"PMC_12767238","title":"Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12767238","citation_count":410,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7529412","id":"PMC_7529412","title":"FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7529412","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18818205","id":"PMC_18818205","title":"Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18818205","citation_count":375,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17012259","id":"PMC_17012259","title":"Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17012259","citation_count":355,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15067080","id":"PMC_15067080","title":"A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15067080","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26053625","id":"PMC_26053625","title":"Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26053625","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43042,"output_tokens":5123,"usd":0.102985},"stage2":{"model":"claude-opus-4-6","input_tokens":8649,"output_tokens":3983,"usd":0.21423},"total_usd":0.817258,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":56662,"output_tokens":12797,"usd":0.180971},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":16828,"output_tokens":5143,"usd":0.319072}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"The human CAMP gene (FALL39) encodes a cathelin precursor protein; proteolytic processing by dipeptidyl-peptidase I cleaves the cathelin prodomain to release the mature 37-amino-acid antimicrobial peptide LL-37 in granulocytes. The gene has four exons, with exons 1-3 encoding the signal sequence and cathelin region, and exon 4 encoding the mature peptide.\",\n      \"method\": \"Gene sequencing, immunolocalization with anti-LL-37 IgG, peptide isolation from degranulated granulocytes, in vitro digestion with dipeptidyl-peptidase I, antimicrobial assay\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biochemical processing demonstrated in vitro and confirmed by isolation of mature peptide from primary human cells\",\n      \"pmids\": [\"8681941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The C-terminal 37-amino-acid domain of human CAP18/hCAP18 (encoded by CAMP) is the active antimicrobial and LPS-binding domain. Synthetic CAP18(104-140) binds LPS-coated erythrocytes, inhibits LPS-induced nitric oxide release from macrophages, inhibits LPS-induced tissue factor generation, and protects mice from LPS lethality.\",\n      \"method\": \"Peptide synthesis, LPS-binding assay (erythrocyte agglutination), macrophage nitric oxide assay, tissue factor assay, mouse endotoxemia model, Western blot with anti-CAP18 antiserum\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal in vitro and in vivo assays in a single study, replicated across rabbit and human CAP18 literature\",\n      \"pmids\": [\"7890387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"CAP18 (the rabbit ortholog of human CAMP-encoded protein) is a granulocyte-derived cationic protein with a signal peptide, a cathelin N-terminal domain, and a C-terminal LPS-binding antimicrobial domain; it bears no homology to other known LPS-binding proteins such as BPI or LBP.\",\n      \"method\": \"cDNA cloning from rabbit bone marrow library, PCR, deduced amino acid sequence analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — foundational cloning and sequence; single study but domain architecture established\",\n      \"pmids\": [\"1883348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The C-terminal 21-residue amphipathic alpha-helical segment of rabbit CAP18 constitutes the primary antibacterial domain; helix disruption virtually eliminates antibacterial activity, and the degree of amphipathicity and the presence of an aromatic residue affect kinetics of bacterial inner membrane permeabilization.\",\n      \"method\": \"Secondary structure prediction, peptide synthesis, bactericidal assay, bacterial inner membrane permeabilization assay, structure-activity relationship with synthetic analogues\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis/analogue approach with in vitro functional assays; replicated across multiple analogues\",\n      \"pmids\": [\"8313956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The active domain of rabbit CAP18 (CAP18(106-137)) adopts a complete rigid alpha-helical conformation in solution (determined by NMR in TFE), with cationic and hydrophobic groups segregated into patches that enable coulombic interaction with LPS diphosphoryl groups and hydrophobic interaction with fatty acyl chains.\",\n      \"method\": \"Circular dichroism, NMR structure determination in 30% TFE\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with functional correlation to LPS binding\",\n      \"pmids\": [\"7649303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Apolipoprotein A-I (apoA-I) is the primary LL-37-binding protein in human plasma; it binds LL-37 with a Kd in the low micromolar range (surface plasmon resonance) and inhibits LL-37 antibacterial activity, functioning as a plasma scavenger/regulator of cathelicidin activity.\",\n      \"method\": \"Affinity chromatography on LL-37 column, SDS-PAGE, N-terminal amino acid sequencing, surface plasmon resonance (BIAcore), antimicrobial assay, anti-apoA-I IgG blocking\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — affinity purification identified binding partner, SPR quantified interaction, functional assay confirmed inhibition, antibody blocking confirmed specificity\",\n      \"pmids\": [\"9837875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CAP18 (rabbit ortholog of human CAMP product) disrupts the outer membrane of gram-negative bacteria by adsorbing to LPS-containing leaflets and forming transient membrane lesions via multimeric clustering; resistance in Proteus mirabilis R45 is due to L-Arap4N modification of LPS that prevents intercalation.\",\n      \"method\": \"Transmission electron microscopy of bacteria, voltage-clamp on planar asymmetric bilayer membranes, FRET, FTIR spectroscopy, film balance measurements\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple biophysical methods reconstituting membrane interaction; structural basis of resistance identified\",\n      \"pmids\": [\"10521271\", \"10931974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human CAP18/LL-37 inhibits LPS-induced TNF-alpha production in macrophages by (1) directly binding LPS and blocking its interaction with LPS-binding protein, and (2) binding cell-surface CD14, thereby preventing LPS docking to CD14+ cells; this dual mechanism was confirmed in vivo in a murine endotoxin shock model.\",\n      \"method\": \"Flow cytometry (FITC-LPS binding to RAW264.7 cells), Northern and Western blot (TNF-alpha mRNA/protein), LPS-binding assay, LPS-LBP interaction assay, murine endotoxin shock model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro assays plus in vivo confirmation; mechanistic pathway placement established\",\n      \"pmids\": [\"11544322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human CAMP/CAP18 gene is located at chromosome band 3p21.3, has no TATA box or CCAAT sequences in its promoter, and is expressed specifically in granulocytes (not in other leukocyte populations), with mRNA expression driven by upstream regulatory sequences that were partially mapped by expression in COS7 cells.\",\n      \"method\": \"Genomic phage library cloning, FISH, somatic cell hybrid PCR mapping, 3' RACE, Northern blot, RT-PCR, Western blot, COS7 cell promoter expression assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mapping and expression characterization; single study\",\n      \"pmids\": [\"8946956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CAMP gene expression is lineage- and stage-specific during neutrophil maturation: CAP18 mRNA transcription peaks at the myelocyte stage in bone marrow, while CAP18 protein accumulates in mature neutrophils, indicating post-transcriptional accumulation of the protein in later maturation stages.\",\n      \"method\": \"Northern blot, Western blot, in situ hybridization, immunohistochemistry of human bone marrow cells at defined maturation stages\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods on primary human cells defining stage-specific expression and protein accumulation\",\n      \"pmids\": [\"9850169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LL-37 transports extracellular self-DNA into monocytes via a TLR-independent mechanism, where cytosolic DNA sensors (requiring STING adaptor protein and TBK1 kinase) recognize the delivered dsDNA and produce type I interferons; this requires double-stranded B-form DNA regardless of sequence, CpG content, or methylation status.\",\n      \"method\": \"Stimulation of primary human monocytes with LL-37/DNA complexes, siRNA knockdown of STING and TBK1, ELISA for type I IFN, specificity controls with different DNA forms\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockdown of specific pathway components (STING, TBK1) with defined cytokine readout; multiple controls establishing pathway position\",\n      \"pmids\": [\"22927244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LL-37 activates keratinocyte IFN-β production by stimulating MAVS (mitochondrial antiviral-signaling protein) together with dsRNA released from necrotic cells, triggering a downstream TBK1-AKT-IRF3 signaling cascade; MAVS was required for LL-37-induced IFN-β in mice, and human psoriatic/wounded skin showed activation of MAVS-associated IRF3.\",\n      \"method\": \"Genetic knockout/knockdown of MAVS, TBK1, IRF3 in keratinocytes; mouse models; IRF3 phosphorylation assays; IFN-β ELISA; human skin gene signature analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function in cells and mice with defined molecular pathway and cytokine readout, confirmed in human tissue\",\n      \"pmids\": [\"27438769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LL-37 activates platelets and augments thrombus formation through formyl peptide receptor 2 (FPR2/ALX); this was established using a pharmacological FPR2 inhibitor and Fpr2/3-deficient mice, which showed abrogated LL-37-induced platelet reactivity, thrombus formation, and shortened tail bleeding time.\",\n      \"method\": \"Platelet activation assays, thrombus formation assays, tail bleeding time in mice, pharmacological FPR2 inhibition, Fpr2/3 knockout mice\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus pharmacological inhibition both confirming receptor identity; multiple platelet functional readouts\",\n      \"pmids\": [\"30413433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LL-37 is internalized into human LAD2 mast cells via clathrin-mediated endocytosis dependent on cell-surface sialic acid (negatively charged), and this internalization requires MrgX2 (a G protein-coupled receptor); siRNA knockdown of MrgX2 inhibited both LL-37 internalization and mast cell degranulation, and MrgX2 overexpression enhanced LL-37 uptake.\",\n      \"method\": \"siRNA knockdown of MrgX2, stable MrgX2 overexpression in HMC-1 and 293 cells, pertussis toxin (G-protein inhibition), neuraminidase treatment (sialic acid removal), clathrin inhibitors (dynasore, chlorpromazine), fluorescence imaging of internalized LL-37, beta-hexosaminidase degranulation assay\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD and overexpression with multiple pharmacological controls; receptor and endocytic pathway both identified\",\n      \"pmids\": [\"30280189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CAMP gene transcription is induced by the histone deacetylase inhibitor Entinostat via sequential activation of STAT3 and HIF-1α transcription factors: STAT3 promotes transcription of CAMP by upregulating HIF-1α expression, and only HIF-1α is directly recruited to the CAMP promoter. This was confirmed in vivo using macrophages from a patient with a STAT3 mutation showing impaired Entinostat-elicited LL-37 induction.\",\n      \"method\": \"Luciferase promoter reporter assay, shRNA knockdown of STAT3 and HIF-1α, selective inhibitors, ChIP assay (HIF-1α recruitment to CAMP promoter), primary macrophages from STAT3-mutant patient\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP identifies direct promoter recruitment; shRNA plus inhibitor approach with human patient validation\",\n      \"pmids\": [\"27633343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LL-37 functions as a transporter of cGAMP (cyclic 2',3'-GMP-AMP): it specifically binds cGAMP and delivers it into target cells, where cGAMP activates STING-dependent interferon responses. Vitamin D3 and sodium butyrate induce CAMP gene expression and consequently enhance LL-37-mediated cGAMP immune responses.\",\n      \"method\": \"Direct binding assay of LL-37 to cGAMP, intracellular delivery assays, STING-dependent IFN response assays, STING knockout controls, CAMP gene induction assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding demonstrated, STING KO confirms pathway dependence, multiple orthogonal methods\",\n      \"pmids\": [\"35649354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LL-37 discriminates between bacterial (target) and host cell membranes through two mechanisms: (1) acidic phospholipids in bacterial membranes cause enhanced membrane binding, and (2) cholesterol and sphingomyelin in host cell plasma membranes attenuate LL-37 intercalation. LL-37 may exert antimicrobial effects by forming cytotoxic oligomers/amyloid-like fibers in acidic phospholipid membranes.\",\n      \"method\": \"Minimum inhibitory concentration assays, dynamic light scattering, monolayer penetration assays, fluorescence spectroscopy with Trp-containing mutant LL-37(F27W), model membranes of defined lipid composition\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted model membrane system with multiple biophysical methods; mechanistic basis for target selectivity established\",\n      \"pmids\": [\"18166145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The C-terminal domain of human CAP18 (hCAP18(109-135)) induces caspase-independent apoptosis in oral squamous cell carcinoma (SAS-H1) cells via mitochondrial depolarization, while sparing normal human gingival fibroblasts and keratinocytes (HaCaT cells).\",\n      \"method\": \"Cell viability assay, mitochondrial membrane potential assay, caspase activation assay, comparison across tumor and normal cell lines\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — defined cellular phenotype (apoptosis, mitochondrial depolarization) with mechanistic observation of caspase independence; single study\",\n      \"pmids\": [\"15279899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LL-37 promotes rapid and efficient delivery of CpG oligodeoxynucleotides to B lymphocytes and plasmacytoid dendritic cells, enabling TLR9-dependent sensing; this delivery function is independent of LL-37's amphipathic structure or bactericidal activity and is selective for cells expressing TLR9 (B cells and pDCs) but not T cells.\",\n      \"method\": \"CpG-ODN stimulation assays in human primary B cells, pDCs, and T cells with/without LL-37; structural LL-37 variants tested; serum and whole blood assays; timing experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional specificity established across multiple cell types; structure-independence shown with variants; single lab\",\n      \"pmids\": [\"20042575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LL-37, acting as a RAGE (receptor for advanced glycation end-products) ligand, induces RAGE-dependent inflammation and alveolar tissue damage in mice, and impairs alveolar epithelial repair responses (organoid-forming efficiency and differentiation); RAGE inhibition or siRNA knockdown reversed these effects in vitro.\",\n      \"method\": \"Intranasal instillation in wild-type and RAGE-deficient mice, precision-cut lung slices, lung organoids, A549 siRNA knockdown of RAGE, RAGE inhibitor FPS-ZM1\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic (KO mice, siRNA) and pharmacological loss-of-function; RAGE identified as LL-37 receptor mediating tissue damage and repair impairment\",\n      \"pmids\": [\"34405719\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CAMP encodes the precursor protein hCAP18, which is cleaved by dipeptidyl-peptidase I at the myelocyte stage of granulocyte differentiation to release the mature 37-amino-acid alpha-helical peptide LL-37; LL-37 kills bacteria by intercalating into acidic-phospholipid-containing membranes and forming membrane-disrupting oligomers, neutralizes LPS by binding it and blocking its interaction with LPS-binding protein and CD14, and modulates innate immunity through multiple receptors (FPR2/ALX on platelets/immune cells, MrgX2 on mast cells, RAGE on epithelial cells) and by chaperoning nucleic acids (DNA, RNA, cGAMP) into endosomal/cytosolic sensors (TLR9, TLR8, cGAS-STING, MAVS-IRF3) to drive type I interferon responses, while plasma apolipoprotein A-I scavenges LL-37 to limit its systemic cytotoxicity.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification:**\n- Papers about CAMP/LL-37/hCAP-18/cathelicidin → KEEP\n- Papers about cAMP (cyclic adenosine monophosphate, the second messenger) → EXCLUDE (alias collision — \"cAMP\" here refers to the second messenger, not the CAMP gene encoding cathelicidin)\n- Papers about 2',3'-cAMP in plants → EXCLUDE (symbol collision)\n\nKEEP papers: [1],[2],[4],[9],[10],[11],[12],[13],[16],[18],[19],[22],[25],[26],[27],[33],[34-wait no],[35],[36],[37],[38],[41],[43],[46],[47-no],[48],[51],[52],[53],[54],[55],[57],[59],[62],[63],[64],[65],[66],[67],[68],[70],[79],[85],[88],[92],[93],[94],[95],[99],[100] from main corpus, plus all gene2pubmed papers.\n\nLet me carefully re-check: Papers [3],[5],[6],[7],[8],[14],[15],[17],[20],[21],[24],[28],[29],[30],[31],[32],[34],[39],[40],[42],[44],[45],[47],[49],[50],[56],[58],[60],[61],[69],[71],[72],[74],[75],[76],[77],[78],[80],[81],[82],[83],[84],[86],[87],[89],[90],[91],[96-wait],97,98 — these are about cAMP second messenger → EXCLUDE.\n\nPaper [96] NETs/LL37/Hippo — KEEP (about LL-37)\nPaper [97] LL-37 and HMGB1/RAGE — KEEP\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"The human CAMP gene (then called FALL39) encodes a cathelin-type precursor protein of 170 amino acids; the mature antibacterial peptide LL-37 is derived from the C-terminal domain (exon 4) after processing, and synthetic FALL-39/LL-37 has potent antibacterial activity against Gram-negative and Gram-positive bacteria. The gene is expressed in bone marrow and testis.\",\n      \"method\": \"cDNA cloning from bone marrow library, PCR, RNA blot, chemical synthesis and antimicrobial assay, CD spectroscopy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original gene characterization with multiple orthogonal methods; replicated by multiple labs\",\n      \"pmids\": [\"7529412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Human CAP18 (CAMP gene product) is expressed specifically in granulocytes; its C-terminal 37-amino-acid domain (CAP18(104-140), equivalent to LL-37) binds LPS, inhibits LPS-induced nitric oxide release from macrophages, inhibits LPS-induced tissue factor generation, and protects mice from LPS lethality.\",\n      \"method\": \"cDNA cloning from bone marrow library, Western blot with specific antiserum, synthetic peptide antimicrobial and LPS-binding assays, in vivo mouse endotoxemia model\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple in vitro and in vivo assays; replicated across labs\",\n      \"pmids\": [\"7890387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The FALL39/CAMP gene has four exons spanning ~1963 bp; exons 1–3 encode the signal sequence and cathelin region, while exon 4 encodes the mature LL-37 peptide. The gene is the only cathelicidin family member in the human genome. Dipeptidyl-peptidase I processing of synthetic FA-LL-37 yields mature LL-37, which is isolated from degranulating granulocytes.\",\n      \"method\": \"Genomic sequencing, exon mapping, anti-LL37 IgG immunolocalization in granulocytes, dipeptidyl-peptidase I processing, antibacterial assay\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete gene structure determined with functional validation; foundational paper\",\n      \"pmids\": [\"8681941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human CAP18 (HCAP18) gene maps to chromosome band 3p21.3, contains 4 exons spanning ~3 kb with ~700 bp upstream sequence, lacks typical TATA or CCAAT boxes, and is expressed specifically in granulocytes as shown by Western, Northern blot and RT-PCR.\",\n      \"method\": \"Genomic phage library cloning, somatic cell hybrid panel PCR mapping, fluorescence in situ hybridization (FISH), Northern blot, RT-PCR, Western blot, promoter mapping in COS7 cells\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — chromosomal mapping and expression characterization with multiple methods\",\n      \"pmids\": [\"8946956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The solution structure of the active C-terminal domain of rabbit CAP18 (CAP18(106-137)) in 30% TFE determined by NMR is a complete, rigid amphipathic alpha-helix. In the presence of lipid A, CAP18(106-137) adopts at least three lipid A concentration-dependent helical conformations, and the cationic and hydrophobic groups segregate to interact with lipid A via coulombic and hydrophobic interactions.\",\n      \"method\": \"Circular dichroism (CD) spectroscopy, NMR spectroscopy in TFE, interaction studies with lipid A\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure determination with functional (lipid binding) validation\",\n      \"pmids\": [\"7649303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The CAMP gene encoding LL-37 is not expressed in normal human skin keratinocytes but is strongly induced in keratinocytes during inflammatory skin disorders (psoriasis, atopic dermatitis, wound healing). In situ hybridization and immunohistochemistry localized the transcript and peptide to keratinocytes throughout inflamed epidermis, and fractions from psoriatic scales exhibited antibacterial activity.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, Northern blot, antibacterial assay of psoriatic scale fractions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods, widely replicated; foundational expression/function paper\",\n      \"pmids\": [\"9182550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The conformation-dependent antibacterial activity of LL-37 was established: LL-37 is disordered in water at low concentration but adopts a cooperative alpha-helical oligomeric structure induced by anions (HCO3−, SO4 2−, CF3CO2−) or increasing peptide concentration. The degree of alpha-helicity directly correlates with antibacterial activity against both Gram-positive and Gram-negative bacteria. Serum inhibits both antibacterial and cytotoxic activities.\",\n      \"method\": \"Circular dichroism (CD) spectroscopy, minimum inhibitory concentration (MIC) assay, cytotoxicity assay, serum inhibition experiment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-function relationship established by CD and activity assays with multiple peptide variants\",\n      \"pmids\": [\"9452503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Apolipoprotein A-I (apoA-I) is the principal LL-37 binding protein in human plasma. ApoA-I was isolated by LL-37 affinity chromatography and binds LL-37 with an apparent Kd in the low micromolar range (surface plasmon resonance). ApoA-I at 50 µM inhibits ~50% of LL-37 antibacterial activity, and anti-apoA-I IgG blocks plasma inhibition of LL-37, indicating apoA-I acts as a scavenger of LL-37 in plasma.\",\n      \"method\": \"Affinity chromatography, SDS-PAGE, amino acid sequence analysis, surface plasmon resonance (Biacore), antimicrobial assay, blocking with anti-apoA-I antibody\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — binding partner identified by affinity chromatography plus kinetics by SPR, functional inhibition confirmed\",\n      \"pmids\": [\"9837875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CAP18/LL-37 is expressed in developing neutrophils in human bone marrow in a lineage- and stage-specific manner: CAMP mRNA is transcribed predominantly at the myelocyte stage, while CAP18 protein accumulates and persists through metamyelocytes, band cells, and segmented neutrophils, indicating post-transcriptional regulation and cytoplasmic storage.\",\n      \"method\": \"Northern blot, Western blot, in situ hybridization, immunohistochemistry of bone marrow cells and mature neutrophils\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods defining spatial and temporal gene expression during differentiation\",\n      \"pmids\": [\"9850169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"LL-37 is chemotactic for human peripheral blood monocytes, neutrophils, and T lymphocytes via formyl peptide receptor-like 1 (FPRL1). LL-37 induces Ca2+ mobilization in monocytes and FPRL1-transfected HEK293 cells, and this mobilization is cross-desensitized by an FPRL1-specific agonist, establishing FPRL1 as a functional receptor for LL-37-mediated leukocyte chemotaxis.\",\n      \"method\": \"Chemotaxis assay, Ca2+ mobilization assay in monocytes and FPRL1-transfected HEK293 cells, cross-desensitization experiment\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor identified by transfection and cross-desensitization; replicated across multiple cell types\",\n      \"pmids\": [\"11015447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"LL-37 is expressed by specific lymphocyte and monocyte populations including NK cells, γδ T cells, B cells, and monocytes/macrophages but not αβ T cells. Primary lymphocyte cultures transcribe and secrete LL-37, and this is modulated by IL-6 and IFN-γ. LL-37 has chemotactic activity for PMNs and CD4+ T lymphocytes.\",\n      \"method\": \"RT-PCR of cell lines, double-staining immunohistochemistry, primary lymphocyte culture, chemotaxis assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell types characterized with RT-PCR and immunohistochemistry; replicated\",\n      \"pmids\": [\"11049988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The human cathelicidin hCAP-18 is cleaved extracellularly by proteinase 3 (from azurophil granules) to generate the active antimicrobial peptide LL-37. Cleavage occurs after exocytosis, not during phagocytosis. Of the three serine proteases from azurophil granules (elastase, cathepsin G, proteinase 3), only proteinase 3 was responsible for this processing.\",\n      \"method\": \"Immunoelectron microscopy, immunoblotting of exocytosed material, selective protease inhibitors, identification of cleaving protease among the three azurophil serine proteases\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — processing enzyme definitively identified with multiple proteases tested; widely cited foundational paper\",\n      \"pmids\": [\"11389039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CAP18 (hCAP18/LL-37) and guinea pig CAP11 inhibit LPS-induced TNF-α expression in macrophages by blocking LPS binding to CD14+ cells. Mechanistically, CAP18 binds LPS with high affinity, competes with LPS-binding protein (LBP) for LPS transport to CD14, and also binds directly to cell surface CD14, thereby blocking LPS-CD14 interaction.\",\n      \"method\": \"Flow cytometry (FITC-LPS binding), Northern blot, Western blot for TNF-α, LPS-binding activity assay, LBP competition assay, in vivo mouse endotoxin shock model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (LPS→LBP→CD14) dissected with multiple methods in vitro and in vivo\",\n      \"pmids\": [\"11544322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"LL-37 is a multifunctional immunomodulator: at physiological concentrations it inhibits LPS, lipoteichoic acid, and noncapped lipoarabinomannan stimulation of macrophages; protects mice from lethal endotoxemia; directly up-regulates 29 macrophage genes including chemokines (MCP-1, IL-8) and chemokine receptors (CXCR-4, CCR2, IL-8RB) without inducing TNF-α; and reduces NF-κB nuclear translocation (p50 and p65 reduced >50%) in LPS-treated cells.\",\n      \"method\": \"Gene expression microarray, RT-PCR, ELISA, NF-κB nuclear translocation assay, in vivo mouse endotoxemia survival assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive transcriptional profiling plus mechanistic NF-κB pathway validation in vitro and in vivo\",\n      \"pmids\": [\"12244186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LL-37/hCAP-18 induces angiogenesis via formyl peptide receptor-like 1 (FPRL1) expressed on endothelial cells. LL-37 directly activates endothelial cell proliferation and tube formation in vitro, promotes neovascularization in the chorioallantoic membrane assay and a rabbit hind-limb ischemia model, and mice deficient for CRAMP (the murine ortholog) show decreased vascularization during wound repair in vivo.\",\n      \"method\": \"In vitro endothelial cell proliferation and tube formation assay, chorioallantoic membrane (CAM) angiogenesis assay, rabbit hind-limb ischemia model, CRAMP-knockout mouse wound healing model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor identified, in vitro mechanism validated, confirmed in vivo with genetic knockout\",\n      \"pmids\": [\"12782669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LL-37 is expressed in healing skin epithelium and is required for re-epithelialization. hCAP18 levels peak at 48 h post-wounding then decline; it is detected in inflammatory infiltrate and migrating epithelium. In an ex vivo organ culture wound model, anti-LL-37 antibodies inhibit re-epithelialization in a concentration-dependent manner and abolish Ki67 (proliferation marker) staining in wound-edge epithelium. LL-37 is markedly reduced in chronic non-healing ulcers.\",\n      \"method\": \"Immunohistochemistry, in situ hybridization, ex vivo wound healing organ culture model with blocking antibody, Ki67 proliferation assay\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional blocking antibody experiment in ex vivo model with proliferation readout\",\n      \"pmids\": [\"12603850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LL-37 disrupts lipid bilayers via a toroidal pore mechanism. Solid-state 15N NMR of site-specifically labeled LL-37 in oriented lipid bilayers shows the amphipathic helix lies parallel to the bilayer surface (ruling out barrel-stave mechanism). 31P NMR shows no micelle/small fragment formation (ruling out detergent-like mechanism), and LL-37 increases the lamellar-to-inverted hexagonal phase transition temperature of PE and E. coli lipids, indicating positive curvature strain consistent with toroidal pore formation.\",\n      \"method\": \"Solid-state 15N NMR (chemical shift and dipolar-shift spectroscopy of isotopically labeled peptide in oriented bilayers), 31P NMR, model membrane lipid phase transition analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural NMR evidence with multiple membrane systems eliminating alternative mechanisms\",\n      \"pmids\": [\"12767238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LL-37 activates the P2X7 receptor to induce caspase-1 activation, IL-1β processing and release from LPS-primed monocytes. LL-37 induces transient ATP release, membrane permeability changes, and IL-1β secretion without cytotoxicity. Pretreatment with P2X7 inhibitors (oxidized ATP, KN04, KN62) suppresses IL-1β release. Apyrase (which hydrolyzes ATP) does not block LL-37's effect, indicating LL-37 directly activates P2X7 rather than acting via autocrine ATP.\",\n      \"method\": \"IL-1β ELISA, caspase-1 activity assay, membrane permeability assay, pharmacological P2X7 inhibitors, apyrase treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — P2X7 as direct receptor established using multiple inhibitors and apyrase control\",\n      \"pmids\": [\"15067080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The C-terminal domain of hCAP18 (hCAP18(109-135)) induces caspase-independent apoptosis selectively in oral squamous cell carcinoma (SAS-H1) cells but not in normal human gingival fibroblasts or HaCaT keratinocytes. The mechanism involves mitochondrial membrane depolarization without caspase activation.\",\n      \"method\": \"Cell viability assay, mitochondrial depolarization assay (JC-1), caspase activation assay, specificity comparison between cancer and normal cells\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (mitochondrial depolarization, caspase-independent) identified in single study\",\n      \"pmids\": [\"15279899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TLR2/1 activation of human macrophages upregulates expression of vitamin D receptor and vitamin D-1-hydroxylase, leading to induction of cathelicidin (CAMP gene product LL-37) and killing of intracellular Mycobacterium tuberculosis. Low serum 25-hydroxyvitamin D in African-American individuals correlates with failure to support cathelicidin mRNA induction, linking vitamin D status to TLR-mediated CAMP gene expression.\",\n      \"method\": \"TLR ligand stimulation of macrophages, RT-PCR for CAMP/VDR/CYP27B1, intracellular M. tuberculosis killing assay, serum 25-hydroxyvitamin D measurement and cathelicidin mRNA induction correlation\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — TLR→VDR→CAMP pathway established with functional antimicrobial readout; highly cited foundational paper\",\n      \"pmids\": [\"16497887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Vitamin D (1,25-dihydroxyvitamin D3) triggers antimicrobial activity against intracellular M. tuberculosis in human THP-1 monocytes via induction of cathelicidin. siRNA knockdown of cathelicidin mRNA and protein expression completely inhibits 1,25D3-induced antimicrobial activity and leads to enhanced intracellular mycobacterial growth, demonstrating that cathelicidin is required for (not merely associated with) this pathway.\",\n      \"method\": \"siRNA knockdown, RT-PCR, Western blot, intracellular M. tuberculosis growth assay in THP-1 cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — causal requirement established by siRNA with direct infectious readout\",\n      \"pmids\": [\"17675463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cathelicidin (LL-37/CRAMP) is essential for urinary tract innate immunity. Epithelial cells of human and mouse urinary tract produce LL-37/hCAP-18 and CRAMP respectively upon bacterial contact. CRAMP-deficient mice and neutrophil-depleted mice show significantly impaired protection against E. coli urinary tract infection. Clinical E. coli strains more resistant to LL-37 cause more severe UTIs, establishing a causal antimicrobial role.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, Western blot of urine, CRAMP-knockout mouse infection model, neutrophil depletion, clinical E. coli strain susceptibility comparison\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with in vivo infection model plus clinical correlation\",\n      \"pmids\": [\"16751768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Kallikrein serine proteases (SCTE/kallikrein-5 and SCCE/kallikrein-7) in the stratum corneum control activation of hCAP18 to LL-37 and further processing to smaller cathelicidin peptides with distinct biological activities. SPINK5-deficient mice (lacking LEKTI serine protease inhibitor) show increased epidermal antimicrobial activity that is ablated by immunoabsorption of cathelicidin, demonstrating that the balance of protease activity at epithelial surfaces controls cathelicidin-mediated innate defense.\",\n      \"method\": \"Selective serine protease inhibitors, SELDI-TOF-MS, Western blot, siRNA for SCTE/SCCE, SPINK5-knockout mice, immunoabsorption of cathelicidin from epidermal extracts, antimicrobial assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — specific processing enzymes identified by siRNA and inhibitors; confirmed in genetic mouse model\",\n      \"pmids\": [\"17012259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LL-37 is the key factor mediating plasmacytoid dendritic cell (pDC) activation in psoriasis. LL-37 binds self-DNA to form aggregated, condensed structures that are delivered to and retained in early endocytic compartments of pDCs, where they trigger TLR9 to induce type I IFN production. This defines LL-37 as a factor that breaks innate tolerance to self-DNA.\",\n      \"method\": \"pDC stimulation assays, IFN-α ELISA, confocal microscopy of LL-37-DNA complex uptake into endosomes, TLR9 reporter assays, gel retardation assay for LL-37-DNA complex structure\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanism (complex formation→endosomal delivery→TLR9 activation) established by multiple methods; widely cited foundational paper\",\n      \"pmids\": [\"17873860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Rosacea skin shows abnormally high cathelicidin (CAMP gene product) levels and unique proteolytically processed cathelicidin peptide forms, resulting from increased stratum corneum tryptic enzyme (SCTE) activity in the epidermis. Injection of rosacea-specific cathelicidin peptides or SCTE into mouse skin increases inflammation. Targeted deletion of Camp in mice confirms that cathelicidin is required for SCTE-mediated skin inflammation.\",\n      \"method\": \"Immunohistochemistry, ELISA, mass spectrometry peptide identification, intradermal injection of peptides in mice, SCTE transgenic mice, Spink5-knockout mice, Camp-knockout mice\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout (Camp-null) confirms causal role; multiple in vivo models\",\n      \"pmids\": [\"17676051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LL-37 binding selectivity between bacterial and host cell membranes is determined by lipid composition: LL-37 intercalates into anionic phospholipid-containing membranes (bacterial membranes) but shows strongly attenuated intercalation into membranes containing both cholesterol and sphingomyelin (characteristic of host cell outer leaflets). LL-37 may form cytotoxic oligomers similarly to amyloid-like peptides in the presence of anionic phospholipids.\",\n      \"method\": \"Minimum inhibitory concentration assay, dynamic light scattering, lipid monolayer penetration, fluorescence spectroscopy with Trp-containing LL-37 mutant (F27W)\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biophysical characterization with functional MIC assay; single lab study\",\n      \"pmids\": [\"18166145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The three-dimensional NMR structure of LL-37 in SDS and dioctanoylphosphatidylglycerol (D8PG) micelles reveals a curved amphipathic helix-bend-helix motif (residues 2–31) with a bend between Gly-14 and Glu-16, followed by a disordered C-terminal tail. Intermolecular NOE cross-peaks between aromatic residues (Phe-5, -6, -17, -27) and arginines with D8PG provide direct evidence for helix association with anionic lipid micelles. The minimal antibacterial peptide KR-12 (residues 18–29) forms a short amphipathic helix with selective toxicity toward bacteria.\",\n      \"method\": \"3D triple-resonance NMR spectroscopy of 13C,15N-labeled LL-37, intermolecular NOE measurements with D8PG micelles, synthetic peptide MIC assay, cytotoxicity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution NMR structure with direct lipid-peptide interaction evidence and structure-activity delineation\",\n      \"pmids\": [\"18818205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LL-37 increases TLR4 mRNA and protein levels in mast cells and induces release of IL-4, IL-5, and IL-1β. When LL-37 co-exists with LPS (TLR4 ligand), Th2 cytokine upregulation is cancelled but pro-inflammatory cytokine augmentation is maintained, demonstrating a switch of mast cell function toward innate immunity.\",\n      \"method\": \"RT-PCR, Western blot, ELISA for cytokines in mast cell (RBL-2H3) cultures treated with LL-37 ± LPS\",\n      \"journal\": \"Biological & pharmaceutical bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional assay with mechanistic interpretation; single lab, single study\",\n      \"pmids\": [\"18239275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LL-37 can bind self-RNA released by dying cells, protect it from extracellular degradation, and transport it into endosomal compartments of plasmacytoid DCs (pDCs) and myeloid DCs (mDCs). Self-RNA–LL-37 complexes activate TLR7 in pDCs (inducing IFN-α) and TLR8 in mDCs (inducing TNF-α/IL-6 and DC maturation). Self-RNA–LL-37 complexes are present in psoriatic skin lesions associated with mature mDCs in vivo.\",\n      \"method\": \"pDC and mDC stimulation assays, IFN-α/TNF-α ELISA, TLR blocking antibodies, TLR7/TLR8 reporter assays, RNA protection assay, immunohistochemistry of psoriatic skin\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — self-RNA transport and differential TLR7/TLR8 activation mechanism established with receptor-specific blocking; replicated\",\n      \"pmids\": [\"19703986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LL-37 transports extracellular self-DNA into monocytes via a TLR-independent pathway. Once inside monocytes, self-DNA activates cytosolic DNA sensors requiring the adaptor protein STING and TBK1 kinase to induce type I IFNs. This activation is mediated by double-stranded B-form DNA regardless of sequence, CpG content, or methylation status.\",\n      \"method\": \"Type I IFN induction assay, pharmacological inhibitors of endosomal TLRs, siRNA knockdown of STING and TBK1, confocal microscopy of DNA uptake, synthetic DNA with varying CpG content/methylation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — STING/TBK1 pathway established by siRNA knockdown; mechanistic dissection with multiple DNA variants\",\n      \"pmids\": [\"22927244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LL-37 and NETs activate the NLRP3 inflammasome in human and murine macrophages, causing caspase-1 activation and release of active IL-1β and IL-18. LL-37 activates NLRP3 via P2X7 receptor-mediated potassium efflux. This inflammasome activation is enhanced in lupus patient macrophages, and IL-18 in turn stimulates further NETosis, creating a feed-forward inflammatory loop.\",\n      \"method\": \"Caspase-1 activation assay, IL-1β/IL-18 ELISA, NLRP3 inflammasome inhibitors, P2X7 inhibitors, potassium efflux measurement, macrophages from lupus patients vs. controls, NETosis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — P2X7/NLRP3 pathway mechanistically established with receptor inhibitors; validated in patient macrophages\",\n      \"pmids\": [\"23267025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LL-37 is a T-cell autoantigen in psoriasis: CD4+ and/or CD8+ T cells specific for LL-37 are present in two-thirds of patients with moderate-to-severe plaque psoriasis, produce IFN-γ and Th17 cytokines, infiltrate lesional skin (tracked by MHC tetramer staining), and their prevalence correlates with disease activity.\",\n      \"method\": \"MHC-peptide tetramer staining, intracellular cytokine staining, flow cytometry, immunohistochemistry of lesional skin biopsies, correlation analysis with PASI score\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tetramer-based T-cell identification is highly specific; LL-37 confirmed as adaptive immune autoantigen in patient cohort\",\n      \"pmids\": [\"25470744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Commensal anaerobic bacteria (clostridial Firmicutes and Bacteroidetes) maintain C. albicans colonization resistance in mice by activating HIF-1α, which induces expression of the cathelicidin CRAMP (murine CAMP ortholog). Pharmacological HIF-1α activation induces CRAMP and reduces C. albicans colonization and mortality. In the presence of antibiotics, Hif1a and Camp (CRAMP) are required for Bacteroides thetaiotaomicron-induced protection.\",\n      \"method\": \"Antibiotic-treated and germ-free mouse models, pharmacological HIF-1α activators, Camp-knockout and Hif1a-knockout mice, C. albicans colonization quantification, survival analysis\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout (Camp-null) establishes causal requirement; HIF-1α→CAMP pathway confirmed in multiple models\",\n      \"pmids\": [\"26053625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LL-37 and double-stranded RNA released from necrotic cells activate MAVS (mitochondrial antiviral-signaling protein) in keratinocytes, triggering a TBK1→AKT→IRF3 signaling cascade that leads to IFN-β production and dendritic cell maturation. MAVS-deficient mice show impaired epidermal IFN-β production by LL-37, and psoriatic/wounded human skin shows MAVS-associated IRF3 activation and IFN-β gene signatures.\",\n      \"method\": \"MAVS-knockout mice, siRNA knockdown of MAVS in keratinocytes, IFN-β ELISA, IRF3 phosphorylation assay, Western blot for TBK1/AKT/IRF3, immunohistochemistry of human psoriatic skin\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complete signaling pathway (LL-37+dsRNA→MAVS→TBK1→AKT→IRF3→IFN-β) established by genetic and siRNA approaches\",\n      \"pmids\": [\"27438769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Histone deacetylase inhibitor Entinostat up-regulates CAMP gene expression via a STAT3→HIF-1α transcriptional axis. Entinostat activates STAT3, which promotes HIF-1α expression; only HIF-1α (not STAT3) is directly recruited to the CAMP promoter. This was confirmed using shRNA knockdown and selective inhibitors, and in macrophages from a STAT3-mutant patient where Entinostat-elicited LL-37 expression was impaired.\",\n      \"method\": \"Luciferase reporter assay (CAMP promoter), shRNA knockdown of STAT3 and HIF-1α, selective inhibitors, ChIP assay showing HIF-1α recruitment to CAMP promoter, macrophages from STAT3-mutant patient\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — STAT3→HIF-1α→CAMP pathway established by ChIP, shRNA, inhibitors, and patient validation\",\n      \"pmids\": [\"27633343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LL-37 activates platelets and enhances thrombus formation via formyl peptide receptor 2 (FPR2/ALX). LL-37 activates a range of platelet functions and shortens tail bleeding time in mice. Using a pharmacological FPR2/ALX inhibitor and Fpr2/3-deficient mice, platelet activation, thrombus formation, and hemostatic effects of LL-37 were abolished, establishing FPR2/ALX as the functional receptor.\",\n      \"method\": \"Platelet aggregation assay, thrombus formation assay (flow chamber), tail bleeding time in mice, pharmacological FPR2/ALX inhibitor, Fpr2/3-knockout mice\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus pharmacological inhibitor confirm FPR2/ALX as the platelet receptor; in vitro and in vivo\",\n      \"pmids\": [\"30413433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MrgX2 (a G protein-coupled receptor) mediates LL-37 internalization and mast cell degranulation. LL-37 is rapidly internalized into LAD2 mast cells via clathrin-mediated endocytosis dependent on negatively charged sialic acid at the cell surface. siRNA knockdown of MrgX2 inhibits both LL-37 internalization and degranulation; MrgX2 overexpression enhances LL-37 internalization. Pertussis toxin (G-protein inhibitor) suppresses both processes. Internalized LL-37 co-localizes with MrgX2 in the perinuclear region.\",\n      \"method\": \"siRNA knockdown of MrgX2, stable MrgX2 overexpression in HMC-1 and HEK293 cells, clathrin endocytosis inhibitors (dynasore, chlorpromazine), pertussis toxin, neuraminidase treatment, β-hexosaminidase degranulation assay, confocal microscopy\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MrgX2 receptor established by siRNA knockdown and overexpression; endocytic pathway mechanistically dissected with multiple inhibitors\",\n      \"pmids\": [\"30280189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Neutrophil extracellular trap (NET)-associated RNA (naRNA) in complex with LL-37 triggers a self-propagating inflammatory cycle in psoriasis. RNA (not canonical NET DNA) complexed with LL-37 activates TLR8/TLR13-mediated cytokine and NET release by primary murine and human neutrophils in vitro and in vivo. Transfer of NETs to naive human neutrophils prompts additional NET release.\",\n      \"method\": \"Primary murine and human PMN stimulation assays, TLR8 and TLR13 blocking/knockout, cytokine ELISA, NET quantification (MPO-DNA ELISA), in vivo neutrophil activation model, RNA vs. DNA complex comparison in psoriatic vs. normal skin\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RNA-LL37 complex as TLR8/13 agonist established with receptor-specific knockouts/blockers; in vivo validation\",\n      \"pmids\": [\"31913271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LL-37 and HMGB1 induce RAGE-dependent alveolar epithelial damage and impair lung tissue repair. Intranasal LL-37 and HMGB1 cause RAGE-dependent inflammation and alveolar tissue damage in mice within 6 h; RAGE-deficient mice are protected. RAGE inhibition reduces recovery from elastase-induced alveolar damage in precision-cut lung slices. In organoids, RAGE ligands reduce organoid-forming efficiency. siRNA knockdown of RAGE in A549 cells confirms RAGE's role in LL-37-induced impaired repair.\",\n      \"method\": \"RAGE-knockout mice, RAGE inhibitor (FPS-ZM1), siRNA knockdown in A549 cells, precision-cut lung slices (PCLS), lung organoids, intranasal instillation model, histology\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RAGE as LL-37 receptor for alveolar damage established by genetic KO, pharmacological inhibition, and siRNA in multiple models\",\n      \"pmids\": [\"34405719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LL-37 functions as a transporter of cyclic 2',3'-GMP-AMP (cGAMP) into target cells. LL-37 specifically binds cGAMP and delivers it intracellularly, activating robust STING-dependent interferon responses and host antiviral immunity. Vitamin D3 and sodium butyrate promote endogenous LL-37 expression and thereby enhance cGAMP-mediated immune responses. This identifies LL-37 as a cGAMP carrier bridging extracellular STING pathway activation.\",\n      \"method\": \"cGAMP-LL-37 binding assay, cell-based cGAMP delivery assay, IFN reporter assay, STING-knockout cells, antiviral immunity assay in vivo, LL-37 induction by vitamin D3/butyrate\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cGAMP transport function established with STING-KO validation and binding assay; novel mechanistic role\",\n      \"pmids\": [\"35649354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The C-terminal 37-amino acid domain of rabbit CAP18 (CAP18(106-142)) is the LPS-binding and antimicrobial domain, with broad bactericidal activity against Gram-positive and Gram-negative bacteria including S. aureus, S. pneumoniae, E. coli, P. aeruginosa, and S. typhimurium. Antimicrobial activity is highly dependent on peptide structure (helix integrity), and a 32-residue truncation from the C-terminus retains high activity while N-terminal truncation abolishes it. Unusually, CAP18(106-142) retains activity in serum.\",\n      \"method\": \"Synthetic peptide MIC assay against multiple bacterial strains, truncation variant activity comparison, serum stability assay\",\n      \"journal\": \"Antimicrobial agents and chemotherapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-activity relationship established with multiple truncation variants; widely cited foundational paper\",\n      \"pmids\": [\"8109914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The primary antibacterial domain of rabbit CAP18 is a 21-residue cationic amphipathic alpha-helical sequence. Synthetic peptide has potent bactericidal activity against Gram-positive and Gram-negative bacteria and rapidly permeabilizes the E. coli inner membrane. Helix disruption (analogue synthesis) virtually eliminates antibacterial activity, while amphipathicity and the presence of an aromatic residue affect the kinetics of inner membrane permeabilization.\",\n      \"method\": \"Secondary structure prediction, synthetic peptide MIC assay, E. coli inner membrane permeabilization assay, synthesis of five analogues with helix-disrupting or amphipathicity-modifying substitutions\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-function relationship established with mutagenesis analogues and membrane permeabilization assay\",\n      \"pmids\": [\"8313956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Rabbit CAP18 interacts with the outer membrane of Gram-negative bacteria by adsorbing to lipopolysaccharide-containing leaflets and forming transient membrane lesions (ion-conducting pores). Electron microscopy shows outer membrane damage in sensitive E. coli but not resistant P. mirabilis R45. Voltage-clamp experiments on asymmetric planar bilayers show that CAP18 adsorbs to LPS-containing leaflets and forms transient current fluctuations (membrane lesions) at a lipid-specific clamp voltage, indicating voltage-dependent reorientation into a transmembrane configuration.\",\n      \"method\": \"Transmission electron microscopy of bacteria, voltage-clamp electrophysiology on planar asymmetric bilayer membranes with LPS or phospholipid leaflets\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — electrophysiological demonstration of membrane pore formation mechanism combined with electron microscopy\",\n      \"pmids\": [\"10521271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Rabbit CAP18 intercalates into LPS-containing lipid matrices from sensitive bacterial strains but only weakly into LPS from resistant P. mirabilis R45 or negatively charged phospholipids, and not at all into neutral phosphatidylcholine. The L-Arap4N modification linked to the first Kdo residue of P. mirabilis R45 LPS is responsible for CAP18 resistance. The depth of intercalation is determined by structural differences in LPS, as shown by combined FRET, FTIR spectroscopy, and film balance measurements.\",\n      \"method\": \"Fluorescence resonance energy transfer (FRET), Fourier-transform infrared spectroscopy (FTIR), film balance (Langmuir trough) measurements on LPS/phospholipid monolayers and liposomes\",\n      \"journal\": \"The Journal of membrane biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic basis of LPS-resistance identified at molecular level using three orthogonal biophysical methods\",\n      \"pmids\": [\"10931974\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CAMP encodes the human cathelicidin precursor hCAP-18, which is processed extracellularly by proteinase 3 to release the active 37-residue LL-37 peptide; LL-37 exerts broad antimicrobial activity by forming toroidal pores in anionic bacterial membranes via an amphipathic alpha-helical structure (NMR-determined), binds LPS to neutralize TLR4 signaling (reducing NF-κB activation), acts as a chemoattractant for neutrophils, monocytes, and T cells via FPRL1/FPR2, activates the P2X7 receptor and NLRP3 inflammasome for IL-1β release, transports self-DNA and self-RNA into endosomal compartments of dendritic cells to activate TLR7/TLR8/TLR9, delivers cGAMP intracellularly to activate STING-dependent antiviral immunity, promotes angiogenesis and wound re-epithelialization via FPRL1 on endothelial cells, activates platelet aggregation and thrombus formation via FPR2/ALX, induces IFN-β in keratinocytes through MAVS–TBK1–AKT–IRF3 signaling, and is transcriptionally regulated by vitamin D (via VDR), by TLRs (via VDR/CYP27B1 induction), by HIF-1α (recruited to the CAMP promoter downstream of STAT3 activation), and post-translationally processed in skin by kallikrein serine proteases (SCTE/SCCE) to generate peptide variants with distinct activities.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CAMP encodes the cathelicidin precursor hCAP18, which is proteolytically processed by dipeptidyl-peptidase I during granulocyte differentiation to release the mature amphipathic alpha-helical antimicrobial peptide LL-37 [PMID:8681941, PMID:9850169]. LL-37 kills bacteria by intercalating into acidic-phospholipid-containing membranes and forming oligomeric pores while sparing cholesterol-rich host membranes, and it neutralizes LPS by directly binding LPS and blocking its interaction with LPS-binding protein and CD14 [PMID:10521271, PMID:18166145, PMID:11544322]. Beyond direct antimicrobial activity, LL-37 functions as a nucleic acid and second-messenger chaperone, transporting self-DNA into the STING–TBK1 cytosolic sensing pathway, delivering CpG-DNA to endosomal TLR9 in B cells and plasmacytoid dendritic cells, shuttling dsRNA to MAVS–IRF3 signaling in keratinocytes, and ferrying cGAMP to activate STING-dependent interferon responses [PMID:22927244, PMID:20042575, PMID:27438769, PMID:35649354]. LL-37 signals through FPR2/ALX on platelets, MrgX2 on mast cells, and RAGE on epithelial cells to modulate thrombosis, degranulation, and tissue repair, while plasma apolipoprotein A-I scavenges LL-37 to limit systemic cytotoxicity [PMID:30413433, PMID:30280189, PMID:34405719, PMID:9837875].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Cloning of rabbit CAP18 revealed that cathelicidins represent a distinct class of LPS-binding antimicrobial proteins with a conserved cathelin prodomain and a C-terminal effector domain, establishing the gene family architecture.\",\n      \"evidence\": \"cDNA cloning from rabbit bone marrow library with sequence analysis\",\n      \"pmids\": [\"1883348\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Human ortholog not yet cloned\", \"Proteolytic activation mechanism unknown\", \"Single study without functional validation of domain boundaries\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Structure-activity studies on the C-terminal peptide established that an amphipathic alpha-helix is essential for bacterial membrane permeabilization, defining the structural basis of cathelicidin antimicrobial activity.\",\n      \"evidence\": \"Synthetic peptide analogues with helix-disrupting substitutions tested in bactericidal and membrane permeabilization assays\",\n      \"pmids\": [\"8313956\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human peptide not yet characterized structurally\", \"Mechanism of membrane disruption at atomic level unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"The C-terminal peptide of human CAP18 was shown to be both the antimicrobial and LPS-neutralizing domain, and NMR structure determination revealed a rigid alpha-helix with segregated cationic and hydrophobic surfaces that engage LPS diphosphoryl and acyl groups respectively.\",\n      \"evidence\": \"Synthetic human CAP18(104-140) in LPS-binding, macrophage nitric oxide, and mouse endotoxemia assays; NMR structure in TFE\",\n      \"pmids\": [\"7890387\", \"7649303\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Processing enzyme and maturation site in vivo not yet identified\", \"Oligomeric state during membrane disruption unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"The human CAMP gene was cloned and mapped to 3p21.3, and dipeptidyl-peptidase I was identified as the processing enzyme that cleaves hCAP18 to release mature LL-37 in granulocytes, resolving how the active peptide is generated.\",\n      \"evidence\": \"Gene sequencing, immunolocalization, peptide isolation from degranulated granulocytes, in vitro digestion with dipeptidyl-peptidase I\",\n      \"pmids\": [\"8681941\", \"8946956\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter elements driving granulocyte-specific expression not fully defined\", \"Whether other proteases contribute in vivo unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that apolipoprotein A-I is the principal plasma scavenger of LL-37 explained how systemic cathelicidin cytotoxicity is limited, establishing a regulatory mechanism for the peptide's bioavailability.\",\n      \"evidence\": \"Affinity chromatography, surface plasmon resonance (Kd measurement), antibody blocking, antimicrobial activity inhibition\",\n      \"pmids\": [\"9837875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether apoA-I binding modulates LL-37 immunomodulatory functions unknown\", \"In vivo stoichiometry not established\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Stage-specific profiling of neutrophil maturation showed that CAMP transcription peaks at the myelocyte stage while protein accumulates in mature neutrophils, indicating post-transcriptional regulation of cathelicidin storage.\",\n      \"evidence\": \"Northern blot, Western blot, in situ hybridization, and immunohistochemistry on human bone marrow cells at defined maturation stages\",\n      \"pmids\": [\"9850169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Post-transcriptional mechanism (translational vs. protein stability) not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Biophysical reconstitution demonstrated that LL-37/CAP18 disrupts gram-negative outer membranes by adsorbing to LPS leaflets and forming transient multimeric pores, while LPS lipid A modification (L-Arap4N) confers bacterial resistance by blocking intercalation.\",\n      \"evidence\": \"Transmission electron microscopy, voltage-clamp on asymmetric planar bilayers, FRET, FTIR, film balance measurements\",\n      \"pmids\": [\"10521271\", \"10931974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oligomer stoichiometry and high-resolution pore structure unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"LL-37 was shown to neutralize LPS signaling by a dual mechanism — direct LPS binding that prevents LPS–LBP interaction and binding to cell-surface CD14 that blocks LPS docking — explaining its anti-endotoxin activity beyond simple LPS sequestration.\",\n      \"evidence\": \"Flow cytometry, Northern/Western blot for TNF-α, LPS-LBP interaction assay, murine endotoxin shock model\",\n      \"pmids\": [\"11544322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LL-37–CD14 interaction affects non-LPS TLR4 ligands not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The basis for LL-37's selectivity for bacterial over host cell membranes was established: acidic phospholipids enhance binding while cholesterol and sphingomyelin in host membranes attenuate intercalation, with cytotoxic oligomer/amyloid-like fiber formation occurring only in bacterial-type membranes.\",\n      \"evidence\": \"Model membranes of defined composition, dynamic light scattering, monolayer penetration assays, fluorescence spectroscopy\",\n      \"pmids\": [\"18166145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether amyloid-like fibers form in vivo at infection sites unconfirmed\", \"Structural details of cytotoxic oligomers not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"LL-37 was found to chaperone CpG-DNA to endosomal TLR9 in B cells and plasmacytoid dendritic cells, revealing a nucleic acid delivery function independent of its amphipathic bactericidal structure and explaining how self-DNA can break innate immune tolerance.\",\n      \"evidence\": \"CpG-ODN stimulation assays in human primary B cells, pDCs, and T cells ± LL-37; structural LL-37 variants tested\",\n      \"pmids\": [\"20042575\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endocytic uptake route of LL-37–CpG complexes not defined\", \"Single-lab finding at time of publication\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"LL-37 was shown to deliver extracellular self-DNA into the cytosol of monocytes to activate the STING–TBK1 pathway and drive type I IFN production, establishing a TLR-independent route by which cathelicidin amplifies sterile inflammation.\",\n      \"evidence\": \"Stimulation of primary human monocytes with LL-37/DNA complexes, siRNA knockdown of STING and TBK1, IFN ELISA\",\n      \"pmids\": [\"22927244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How LL-37–DNA complexes escape endosomes to reach cytosolic sensors unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"LL-37 was found to activate keratinocyte IFN-β via MAVS–TBK1–IRF3 signaling in cooperation with dsRNA, extending the nucleic acid chaperoning function to a second cytosolic sensing axis relevant to psoriasis and wound healing.\",\n      \"evidence\": \"Genetic knockout/knockdown of MAVS, TBK1, IRF3 in keratinocytes and mice; IRF3 phosphorylation; human psoriatic skin analysis\",\n      \"pmids\": [\"27438769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LL-37 directly binds dsRNA or facilitates its uptake not distinguished\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CAMP transcriptional regulation was linked to STAT3–HIF-1α signaling: STAT3 induces HIF-1α, which is directly recruited to the CAMP promoter, explaining how HDAC inhibitors and inflammatory signals upregulate cathelicidin expression.\",\n      \"evidence\": \"ChIP assay showing HIF-1α recruitment to CAMP promoter, shRNA knockdown of STAT3 and HIF-1α, STAT3-mutant patient macrophages\",\n      \"pmids\": [\"27633343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether vitamin D response element and HIF-1α site cooperate at the CAMP promoter not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of FPR2/ALX and MrgX2 as LL-37 receptors on platelets and mast cells, respectively, established that cathelicidin modulates thrombosis and mast cell degranulation through specific GPCRs rather than nonspecific membrane effects.\",\n      \"evidence\": \"FPR2 pharmacological inhibition and Fpr2/3 knockout mice for platelet activation; MrgX2 siRNA knockdown and overexpression for mast cell internalization and degranulation\",\n      \"pmids\": [\"30413433\", \"30280189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascades from each GPCR not fully mapped\", \"Whether LL-37 binds FPR2 and MrgX2 simultaneously in complex tissues unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"RAGE was identified as an LL-37 receptor on alveolar epithelial cells, mediating LL-37-induced lung inflammation and impairment of alveolar repair, demonstrating that cathelicidin can drive tissue damage through a non-GPCR receptor.\",\n      \"evidence\": \"RAGE-deficient mice, siRNA knockdown, pharmacological RAGE inhibitor FPS-ZM1, lung organoids\",\n      \"pmids\": [\"34405719\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biophysical binding of LL-37 to RAGE ectodomain not demonstrated\", \"Whether RAGE mediates LL-37 signaling in non-lung epithelia unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"LL-37 was shown to directly bind and transport cyclic dinucleotide cGAMP into cells to activate STING-dependent interferon signaling, expanding the chaperone function beyond nucleic acids to a second messenger of innate immunity.\",\n      \"evidence\": \"Direct LL-37–cGAMP binding assay, intracellular delivery assays, STING knockout controls\",\n      \"pmids\": [\"35649354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding affinity and stoichiometry of LL-37–cGAMP complex not quantified\", \"Whether LL-37 transports other cyclic dinucleotides (c-di-GMP, c-di-AMP) not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis by which LL-37 selectively binds and delivers diverse cargoes (DNA, RNA, cGAMP) to distinct intracellular sensors, and how cargo identity determines receptor pathway selection (STING vs. TLR9 vs. MAVS), remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No co-crystal or cryo-EM structure of LL-37 bound to any nucleic acid or cGAMP cargo\", \"Mechanism of endosomal escape of LL-37–cargo complexes undefined\", \"Relative contribution of each receptor pathway (FPR2, MrgX2, RAGE) to net immunomodulation in vivo not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 4, 6, 7, 16]},\n      {\"term_id\": \"GO:0090729\", \"supporting_discovery_ids\": [0, 1, 3, 6, 16]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [10, 15, 18]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [12, 13, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 5, 6, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0168256\", \"supporting_discovery_ids\": [10, 11, 15, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11, 15, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 13, 19]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"APOA1\",\n      \"CD14\",\n      \"FPR2\",\n      \"MRGPRX2\",\n      \"AGER\",\n      \"TMEM173\",\n      \"TBK1\",\n      \"MAVS\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CAMP encodes the sole human cathelicidin, hCAP-18, which is processed extracellularly by proteinase 3 in neutrophils—and by kallikrein serine proteases (KLK5/KLK7) in skin—to release the amphipathic α-helical peptide LL-37 that kills bacteria by forming toroidal pores in anionic membranes [PMID:11389039, PMID:12767238, PMID:17012259]. Beyond direct antimicrobial activity, LL-37 functions as a multifaceted immunomodulator: it neutralizes LPS by competing with LBP for CD14 binding, recruits leukocytes via FPRL1/FPR2, activates the P2X7–NLRP3 inflammasome axis for IL-1β release, transports self-DNA and self-RNA into endosomes to trigger TLR7/TLR8/TLR9-mediated type I interferon production, delivers cGAMP intracellularly to activate STING-dependent antiviral responses, and promotes angiogenesis and wound re-epithelialization through FPRL1 on endothelial cells [PMID:11015447, PMID:12244186, PMID:23267025, PMID:17873860, PMID:19703986, PMID:35649354, PMID:12782669]. CAMP transcription is induced by vitamin D via VDR downstream of TLR2/1 signaling and by HIF-1α recruited to the CAMP promoter through STAT3, linking innate immune sensing and metabolic cues to cathelicidin-dependent host defense against pathogens including Mycobacterium tuberculosis and uropathogenic E. coli [PMID:16497887, PMID:27633343, PMID:16751768]. LL-37 also breaks innate tolerance to self-nucleic acids—serving as an autoantigen recognized by T cells in psoriasis—and drives pathological inflammation in psoriasis and rosacea through aberrant protease processing and TLR activation [PMID:25470744, PMID:17676051, PMID:31913271].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of the C-terminal domain of CAP18 as the minimal LPS-binding and bactericidal module established that cathelicidins concentrate antimicrobial function in a short cationic α-helical segment whose integrity is essential for activity.\",\n      \"evidence\": \"Synthetic truncation variants tested in MIC assays against multiple bacterial species, with serum stability evaluation (rabbit CAP18)\",\n      \"pmids\": [\"8109914\", \"8313956\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human LL-37 peptide not yet identified\", \"Processing enzyme in vivo unknown\", \"Mechanism of membrane killing unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Cloning of the human CAMP gene revealed that LL-37 is the only human cathelicidin, with broad-spectrum antibacterial activity and LPS-neutralizing capacity that protects against endotoxemia in vivo, establishing a dual antimicrobial and anti-inflammatory role.\",\n      \"evidence\": \"cDNA cloning from bone marrow, synthetic LL-37 antimicrobial assays, LPS-binding assays, mouse endotoxemia survival model\",\n      \"pmids\": [\"7529412\", \"7890387\", \"7649303\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo processing enzyme unknown\", \"Mechanism of LPS neutralization at receptor level unresolved\", \"NMR structure of human LL-37 not yet determined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Complete genomic characterization placed CAMP at 3p21.3 with four exons and defined its granulocyte-restricted expression during myeloid differentiation, revealing that transcription peaks at the myelocyte stage while protein accumulates through terminal neutrophil maturation.\",\n      \"evidence\": \"FISH mapping, somatic cell hybrid PCR, Northern/Western blot of bone marrow differentiation stages, immunohistochemistry\",\n      \"pmids\": [\"8681941\", \"8946956\", \"9850169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulation of transcription beyond myeloid commitment unknown\", \"Post-transcriptional storage mechanism not characterized\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Structure-activity studies demonstrated that LL-37's antibacterial potency depends on anion-induced cooperative α-helical oligomerization, and identification of apolipoprotein A-I as a plasma scavenger explained why serum attenuates LL-37 activity.\",\n      \"evidence\": \"CD spectroscopy with anion titrations, MIC assays, affinity chromatography, SPR binding kinetics, anti-apoA-I blocking antibody\",\n      \"pmids\": [\"9452503\", \"9837875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oligomeric state and stoichiometry on bacterial membranes unknown\", \"In vivo relevance of apoA-I scavenging during infection unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery that LL-37 is chemotactic for monocytes, neutrophils, and T cells via FPRL1/FPR2 receptor transformed understanding of cathelicidin from a simple antimicrobial to an immune cell recruiter bridging innate and adaptive immunity.\",\n      \"evidence\": \"Chemotaxis assays, Ca²⁺ mobilization in FPRL1-transfected HEK293 cells, cross-desensitization with FPRL1-specific agonists, expression in NK cells, γδ T cells, monocytes\",\n      \"pmids\": [\"11015447\", \"11049988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream FPRL1 signaling cascade not mapped\", \"Relative contribution of chemotaxis vs. antimicrobial activity in vivo unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of proteinase 3 as the specific extracellular processing enzyme for hCAP-18→LL-37 after neutrophil degranulation, combined with the mechanism of LPS neutralization via competitive blockade of LBP–CD14 interaction, defined the activation and anti-endotoxin pathways.\",\n      \"evidence\": \"Immunoelectron microscopy, selective protease inhibitor panel, LPS–CD14 binding competition, in vivo endotoxin model\",\n      \"pmids\": [\"11389039\", \"11544322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific processing enzymes outside neutrophils unknown\", \"Kinetics of proteinase 3 cleavage at infection sites not determined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"LL-37 was shown to form toroidal pores in bacterial membranes (not barrel-stave or detergent-like), to promote angiogenesis and wound re-epithelialization via FPRL1 on endothelial cells, and to be required for skin repair—expanding its role from antimicrobial defense to tissue regeneration.\",\n      \"evidence\": \"Solid-state ¹⁵N/³¹P NMR in oriented bilayers, CAM angiogenesis assay, CRAMP-knockout mouse wound model, ex vivo human wound model with anti-LL-37 blocking antibody\",\n      \"pmids\": [\"12767238\", \"12782669\", \"12603850\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pore size and stoichiometry not resolved\", \"Signaling pathway downstream of FPRL1 in endothelial cells not elucidated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"LL-37 was found to directly activate the P2X7 receptor on monocytes to trigger caspase-1 and IL-1β release independently of autocrine ATP, establishing it as an endogenous danger signal coupling antimicrobial peptide release to inflammasome activation.\",\n      \"evidence\": \"P2X7 pharmacological inhibitors (oxidized ATP, KN04, KN62), apyrase control, IL-1β ELISA, caspase-1 assay in LPS-primed monocytes\",\n      \"pmids\": [\"15067080\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biophysical interaction between LL-37 and P2X7 not demonstrated\", \"NLRP3 involvement not yet tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"A TLR2/1→VDR→CYP27B1→vitamin D→CAMP transcriptional axis was discovered in macrophages, causally linking vitamin D sufficiency to cathelicidin-dependent killing of intracellular M. tuberculosis; concurrently, CRAMP-knockout mice revealed cathelicidin's essential role in urinary tract defense, and kallikrein proteases were identified as skin-specific processing enzymes generating diverse cathelicidin peptide forms.\",\n      \"evidence\": \"TLR-stimulated macrophages with vitamin D measurements, siRNA knockdown of CAMP abolishing mycobacterial killing, CRAMP-KO UTI model, SCTE/SCCE siRNA and SPINK5-KO mice for skin processing\",\n      \"pmids\": [\"16497887\", \"17675463\", \"16751768\", \"17012259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"VDR binding site in CAMP promoter not mapped at nucleotide resolution in this work\", \"Clinical vitamin D supplementation efficacy for TB unproven\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"LL-37 was discovered to break innate tolerance to self-DNA by condensing extracellular DNA into aggregates that resist degradation, delivering them into early endosomes of plasmacytoid DCs to activate TLR9 and drive type I IFN—establishing the mechanism for LL-37-mediated autoimmune amplification in psoriasis and linking aberrant cathelicidin processing to rosacea pathogenesis.\",\n      \"evidence\": \"pDC IFN-α assays, TLR9 reporter, confocal microscopy of LL-37–DNA endosomal uptake, gel retardation; Camp-KO mice for rosacea; MHC tetramer identification of LL-37-specific T cells in psoriasis patients\",\n      \"pmids\": [\"17873860\", \"17676051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LL-37–DNA condensation unknown\", \"Why some individuals develop autoimmune responses to LL-37 while others do not is unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The three-dimensional NMR structure of LL-37 in lipid micelles revealed a curved helix-bend-helix amphipathic architecture with direct lipid contacts via aromatic and cationic residues, and defined KR-12 (residues 18–29) as the minimal bactericidal core—providing the first atomic-resolution template for the human cathelicidin.\",\n      \"evidence\": \"3D triple-resonance NMR of ¹³C,¹⁵N-labeled LL-37, intermolecular NOEs with D8PG micelles, MIC assays of KR-12\",\n      \"pmids\": [\"18818205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of LL-37 in a membrane bilayer context\", \"Oligomeric pore structure not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extension of the nucleic acid transport paradigm to self-RNA showed that LL-37–RNA complexes differentially activate TLR7 in pDCs and TLR8 in mDCs, broadening the mechanism of innate tolerance breaking beyond DNA to include RNA sensing.\",\n      \"evidence\": \"pDC/mDC stimulation assays, IFN-α/TNF-α ELISA, TLR7/TLR8 blocking antibodies and reporter assays, RNA protection assay, immunohistochemistry of psoriatic skin\",\n      \"pmids\": [\"19703986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural determinants governing LL-37 preference for RNA vs. DNA unknown\", \"Relative contribution of TLR7 vs. TLR8 pathway in psoriasis not quantified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Two cytosolic sensing pathways were linked to LL-37: transport of self-DNA into monocytes activates the STING–TBK1 axis for type I IFN (TLR-independent), and LL-37 activates P2X7-dependent K⁺ efflux to trigger the NLRP3 inflammasome in macrophages, creating a feedforward loop with NETosis in lupus.\",\n      \"evidence\": \"siRNA knockdown of STING and TBK1, NLRP3 inhibitors, P2X7 inhibitors, potassium efflux measurement, lupus patient macrophages\",\n      \"pmids\": [\"22927244\", \"23267025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How LL-37 escapes endosomes to deliver DNA to cytosolic STING unknown\", \"Therapeutic targetability of the NET–LL-37–NLRP3 loop not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"LL-37 was identified as a T-cell autoantigen in psoriasis, with LL-37-specific CD4⁺/CD8⁺ T cells infiltrating lesional skin and correlating with disease severity, definitively linking cathelicidin to adaptive autoimmunity.\",\n      \"evidence\": \"MHC-peptide tetramer staining, intracellular cytokine profiling, flow cytometry, skin biopsy immunohistochemistry, PASI correlation\",\n      \"pmids\": [\"25470744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HLA restriction elements for all LL-37 epitopes not fully defined\", \"Whether LL-37-specific T cells are pathogenic drivers or bystanders not formally proven\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Transcriptional regulation of CAMP was extended to a STAT3→HIF-1α axis (HIF-1α directly recruited to the CAMP promoter), and LL-37 was shown to activate MAVS→TBK1→AKT→IRF3→IFN-β signaling in keratinocytes when complexed with dsRNA, linking cathelicidin to cytosolic antiviral sensing beyond TLR pathways.\",\n      \"evidence\": \"ChIP showing HIF-1α at CAMP promoter, shRNA/inhibitor knockdowns, STAT3-mutant patient macrophages; MAVS-KO mice, siRNA in keratinocytes, psoriatic skin IFN-β gene signatures\",\n      \"pmids\": [\"27633343\", \"27438769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HIF-1α and VDR cooperate or act independently at the CAMP promoter not resolved\", \"Relative contribution of MAVS vs. TLR pathways in skin inflammation not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"LL-37's receptor repertoire was expanded to include FPR2/ALX on platelets (mediating thrombus formation, confirmed in Fpr2/3-KO mice) and MrgX2 on mast cells (mediating degranulation via clathrin-dependent endocytosis), establishing LL-37 as a multi-receptor signaling ligand in hemostasis and allergy.\",\n      \"evidence\": \"FPR2/ALX inhibitor + Fpr2/3-KO mice for platelet aggregation/bleeding time; MrgX2 siRNA/overexpression, endocytosis inhibitors, confocal co-localization in mast cells\",\n      \"pmids\": [\"30413433\", \"30280189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LL-37 promiscuity across GPCRs (FPRL1, FPR2, MrgX2) unknown\", \"In vivo relevance of mast cell MrgX2 activation by LL-37 in disease settings not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that LL-37 binds and transports cGAMP intracellularly to activate STING-dependent antiviral immunity added a cell-extrinsic second messenger delivery function, positioning cathelicidin as a carrier that bridges extracellular danger signals to cytosolic innate sensors.\",\n      \"evidence\": \"cGAMP-LL-37 binding assay, STING-KO cell IFN reporter, antiviral assay in vivo, LL-37 induction by vitamin D3/butyrate\",\n      \"pmids\": [\"35649354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and affinity of cGAMP–LL-37 complex not determined\", \"Whether other cathelicidins share cGAMP transport capacity unknown\", \"Endosomal escape mechanism for cGAMP delivery to cytosolic STING not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of the LL-37 oligomeric pore in a membrane bilayer, the mechanism by which LL-37-cargo complexes escape endosomes to access cytosolic sensors (STING, MAVS), and whether the multiple receptor interactions (FPRL1, FPR2, P2X7, MrgX2, RAGE) operate cooperatively or in cell-type-specific isolation during infection and autoimmunity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of LL-37 pore in a bilayer\", \"Endosomal escape mechanism unknown\", \"Integrated signaling model across multiple receptors lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0090729\", \"supporting_discovery_ids\": [0, 1, 6, 40, 41]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [4, 16, 25, 26, 43]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [9, 14, 35]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [23, 28, 29, 39]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [12, 13, 17, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 7, 11, 22]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [23, 28, 36]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 10, 13, 17, 19, 20, 23, 28, 29, 30, 33, 37, 39]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 14, 17, 29, 30, 33, 34, 35, 38]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 24, 28, 31, 37, 38]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FPR2\",\n      \"P2X7R\",\n      \"MRGPRX2\",\n      \"AGER\",\n      \"PRTN3\",\n      \"KLK5\",\n      \"KLK7\",\n      \"APOA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}